Locally recurrent rectal cancer : aspects on management, surgery and outcome by Westberg, Karin
Department of Molecular Medicine and Surgery (MMK) 
Colorectal Surgery Research Group 
Karolinska Institutet 
Stockholm, Sweden 
LOCALLY RECURRENT RECTAL CANCER 
– ASPECTS ON MANAGEMENT, SURGERY 
AND OUTCOME 
Karin Westberg 
 
Stockholm 2017 
 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-Print AB 2017 
© Karin Westberg, 2017 
ISBN 978-91-7676-815-0 
Locally recurrent rectal cancer – aspects on 
management, surgery and outcome 
 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Karin Westberg 
 
 
 
 
Principal Supervisor: 
Prof. Anna Martling 
Karolinska Institutet 
Department of Molecular Medicine and Surgery 
 
 
Co-supervisor(s): 
Ph.D. Gabriella Palmer 
Karolinska Institutet 
Department of Molecular Medicine and Surgery 
 
 
Ass. Prof. Fredrik Hjern 
Karolinska Institutet 
Department of Clinical Sciences 
 
  
Prof. Torbjörn Holm 
Karolinska Institutet 
Department of Molecular Medicine and Surgery 
 
 
Opponent: 
Prof. Emmanuel Tiret 
Universités-Praticien Hospitalier, Paris VI 
Department of Medicine, Pierre and Marie Curie 
 
 
Examination Board: 
Prof. Magnus Nilsson 
Karolinska Institutet 
Department of Clinical Science, Intervention and 
Technology 
 
 
Prof. Maria Albertsson 
Syddansk Universitet 
Division of Oncology 
 
 
Prof. Eva Haglind 
Göteborgs Universitet 
Department of Clinical Sciences 
 
 
 
ABSTRACT 
 
Locally recurrent rectal cancer (LRRC) is a severe condition associated with a high morbidity and 
mortality, affecting about 150-200 people/year in Sweden. After improvements in management and 
treatment of primary rectal cancer (RC), including an amelioration and standardisation of surgical 
technique, improved preoperative staging, addition of preoperative radiotherapy (RT), implementation of 
multidisciplinary team conferences and postoperative surveillance programmes, the rate of LRRC has 
decreased dramatically from 30-40% to 5-15%. A curative surgical resection is necessary for a 
favourable prognosis and five-year survival rates of more than 60% have been reported after curative 
surgery. However, when looking at all patients with LRRC, the survival rate drops below 10%. The aim 
of this thesis was to learn more about the characteristics, management and outcome of patients with 
LRRC in Sweden. 
Paper I aimed at investigating whether the time interval from primary surgery of RC to diagnosis of 
LRRC had any impact on survival after LRRC diagnosis. Population-based data on patients operated for 
primary RC during the period 1995-2002 and with a diagnosis of LRRC as first event reported to the 
Swedish Colorectal Cancer Registry (SCRCR) were accessed from the registry. 386 patients were 
included, of which 25% had an early LRRC (ELR) and 75% had a late LRRC (LLR). Patients with a 
stage III primary tumour and non-irradiated patients were significantly more common in the ELR group. 
Factors that influenced survival were age, stage of primary tumour and surgical resection of the LRRC. 
Time to diagnosis of LRRC did not influence survival and should not be taken into account in treatment 
decisions of LRRC patients. 
The aim of paper II was to assess what factors affect treatment intention in patients with LRRC. 
Medical records of patients defined by the same criteria as in paper I were collected and analysed. 426 
patients were included, of which 35% had been treated with curative intent and 65% with palliative 
intent. Factors significantly associated with palliative treatment intention were age ≥80 years, presence 
of symptoms and a non-central location of the LRRC. The same factors also increased the risk of death 
among patients treated with curative intent. Five-year survival was 23% for patients treated with curative 
intent and 9% for all LRRC patients. The results present a congruence between factors predictive for 
treatment and prognostic factors, indicating an adequate selection for treatment. 
In paper III, an analysis of time trends, regional variations and prognosis of the same patients as in 
paper II was performed. 28% of the patients were treated with tumour resection with curative intent. No 
significant time trends or regional variations were seen regarding treatment intention or resection 
margins after surgery for LRRC. The proportion of patients with non-central recurrences increased over 
time. Patients with a centrally located tumour were more likely to have a radical tumour resection. Five-
year survival rates were 43% for patients treated with R0 resection and 14% after R1 resection. The 
results confirm that negative resection margins are crucial for a favourable prognosis in patients with 
LRRC. 
In paper IV, details on surgical treatment of the LRRC in the patient cohort included in paper II and III 
were evaluated. 35% were treated with tumour resection, 19% had surgery without tumour resection and 
20% were treated with best supportive care. Abdominoperienal resection was the most commonly 
performed resection procedure, performed in 49% of the abdominally resected patients. In total, 49% of 
the patients had a multi-organ resection and another 10% had a total pelvic exenteration. Complications 
were more common after tumour resection than after surgery without tumour resection, but the 
postoperative mortality was significantly higher among non-resected patients. Complications should be 
avoided, possibly by a better selection for surgery. 
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1 BACKGROUND 
 
1.1 RECTAL CANCER 
1.1.1 Epidemiology 
Colorectal cancer (CRC) is the third most common type of cancer worldwide, with 1.4 million 
new cases each year and 700 000 deaths in 20122. The highest incidence of CRC is found in 
high-income developed countries, particularly in Australia, New Zealand, Europe and Northern 
America, while the rates are low in Africa and South and Central Asia3. The differences in 
geographical distribution are most likely explained by a varying exposure to life-style related 
risk factors2. CRC is more common in men than in women throughout the world, for unknown 
reasons. The life-time risk of CRC in the general population is 4-5%4. The disease is uncommon 
before 50 years of age and the incidence thereafter rises with age. The global burden of CRC is 
increasing and by 2030, 2.2 million new cases and 1.1 million CRC-related deaths are expected. 
However, a trend of decreasing both incidence and mortality is observed in Australia, Iceland, 
New Zealand, Japan and the USA, while an increasing incidence and reduced mortality is seen 
in Northern and Central Europe2. The decreasing mortality rate in these countries is thought to 
be attributed to increased CRC screening, altered risk factor pattern and improved treatment5.  
 
 
Figure 1 Map illustrating the age-standardised incidence of colorectal cancer per 100 000 
inhabitants for men and women in 2012. Reprinted with permission from GLOBOCAN 2012, 
International Agency for Research on Cancer6 
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In Sweden, about 6000 new cases of CRC are diagnosed each year and of these, approximately 
one third have rectal cancer (RC). Less than half of the patients (40%) are women. The overall 
incidence is slowly increasing, while the age-standardised incidence has been stable over the 
last 15 years. The relative survival has increased dramatically during the last 30 years. Current 
five year-survival in men is 63% and 64% in women and the 10 year-survival is 54% and 58% 
respectively7. 
 
a) 
 
1.1.2 Pathogenesis and risk factors 
Sugarbaker et al suggested in 1985 that most malignant colorectal tumours arise from benign 
adenomas8. After further exploration of the process, it has become widely accepted that 
adenomas are the precursors of colorectal cancer, which develops through a multistep process 
triggered by mutations leading to the activation of oncogenes and inactivation of tumour 
suppressor genes9,10. It is estimated that 95% of colorectal neoplasms develop from benign 
adenomas. However, adenomas are common, present in 15-35% of asymptomatic adults11,12, 
and only 10% become neoplastic13. The risk of malignification is related to both the number and 
size of the adenomas. Since the development from adenoma to colorectal neoplasm takes 
several years, early finding may prevent a fulminant development of colorectal cancer. 
Screening programs leading to early detection and removal of adenomas have been shown to 
reduce the risk of CRC and prolong overall survival 14-18.  
Among known non-modifiable risk factors for CRC, age, hereditary syndromes and a history of 
inflammatory bowel disease (IBD) are the most important ones. About 20-25% of CRC cases 
are caused by inherited factors and 5-10% are the result of known genes predisposing for a 
colorectal syndrome, including the Lynch syndrome, familial adenomatous polyposis (FAP) and 
MYH-associated polyposis (MAP) as the most common19,20. The remaining 75-80% of all CRC 
tumours arise sporadically, without genetic predisposition to the disease. The association 
Figure 2 Age-standardised incidence (blue) and mortality (red) per 100 000 inhabitants in 
Sweden between 1970-2015 among a) men and b) women 1. Reprint with permission. 
b) 
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between IBD and CRC is well supported and the risk increases with duration of the disease, 
with 8% risk at 20 years and 18% risk at 30 years of IBD21,22. Much interest has been directed 
towards the influence of lifestyle factors on the risk of developing CRC, but few significant 
factors have been verified. Obesity and a high intake of red meat, tobacco and alcohol are 
factors suggested to increase the risk of colorectal cancer, while a high fibre intake, physical 
activity and long-term use of aspirin are factors believed to have a protective effect23-25.  
 
1.1.3 Anatomy 
Minor variations in the definition of the rectum exist, but it is generally described as the final 15 
cm of the large bowel, beginning at the rectosigmoid junction and ending at the anal verge. In 
surgical practice, the sacral promontory is regarded as the upper landmark from which the 
rectum extends down towards the pelvic floor, where it transforms into the anal canal. The 
rectum is enfolded by the mesorectum, a fatty lymphovascular tissue, which in turn is 
surrounded by the avascular perirectal fascia. The mesorectum is thicker posteriorly and 
laterally and thins out as it reaches the anorectal junction26. The main arterial blood supply 
derives from the inferior mesenteric artery, which arises from the aorta. After giving off 
branches to the left colon and sigmoid, the remaining branch named the superior rectal artery 
subdivides into right and left branches which supply the rectum. The middle and inferior 
hemorrhoid arteries both derive from the internal iliac artery and together supply the distal 
portion of the rectum. Knowledge of vascular anatomy is essential in colorectal cancer surgery, 
as the lymphatic drainage and potential cancer spread follows the same routes as the large 
vessels27.  
The upper third of the rectum is circumferentially surrounded by peritoneum, while the middle 
third is covered anteriorly by peritoneum and posteriorly has a retroperitoneal position. The 
most distal part of the rectum, below the rectouterine pouch, is completely retroperitoneal. The 
rectum has close proximity to other organs and is anteriorly limited by the prostate, seminal 
vesicles, vas and urinary bladder in men and the upper vagina and uterus in women, posteriorly 
by the sacrum, coccyx and sacral nerves and laterally by the urethers, iliac vessels and the 
lateral pelvic wall. It is also common that part of the small intestine, the sigmoid colon or the 
ovaries fill out the remaining intraperitoneal space of the lesser pelvis leading to tumour 
engagement of these organs in cases of locally advanced RC or LRRC27. The proximity to other 
vital organs as well as the natural narrowness of the pelvis has a high impact on the planning 
and performance of rectal cancer treatment, both regarding surgery and radiotherapy (RT). 
The pelvic floor resembles a muscular mat that keeps pelvic organs in place, only allowing 
passage of the rectum, urethra and (in women) vagina and maintaining urine and faecal 
continence. The largest constituent muscle, the puborectal muscle, forms a loop around the 
rectum and its most adjacent part makes up the external anal sphincter, which is innervated by 
sympathetic fibres and has a vital function in defecation and anal continence. The internal 
sphincter is innervated by parasympathetic fibres and is formed by a thickened part of the 
muscular layer of the bowel wall inside the external sphincter. 
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1.1.4 Preoperative assessment and staging 
1.1.4.1 Clinical investigation 
Common initial symptoms of RC are altered bowel habits, rectal bleeding and incomplete 
bowel evacuation, whereas anaemia, abdominal pain, anal incontinence, weight loss and fatigue 
are symptoms of a more advanced disease. Since the introduction of screening programmes 
with faecal blood test and/or colonoscopy in healthy individuals, a number of patients are today 
asymptomatic at time of diagnosis. After clinical examination with rectal palpation, a 
rectoscopy and a colonoscopy with biopsies from the visualised tumour are often the next steps 
of the assessment. A colonoscopy with biopsies is usually sufficient for a diagnosis and is also 
important to rule out synchronous tumours in the colon. An examination with a rigid 
rectoscope, however, serves an additional purpose, allowing for a more reliable estimation of 
the distance of the tumour from the anal verge. According to international guidelines, the 
tumour height is then classified as either low (0-5 cm), median (6-10 cm) or high (11-15 cm)28. 
The height of the tumour is one of many factors that determines further type of treatment. 
1.1.4.2 Computed tomography 
Contrast-enhanced computed tomography (CT) of the chest and abdomen is the method of 
choice to demonstrate or rule out synchronous distant metastases, primarily in the liver or lungs. 
The sensitivity for the detection of pulmonary metastases by CT is high, 99%. The transition 
from the previously used chest x-ray to CT has however entailed an increased finding of lung 
lesions that are too small to allow for a diagnosis. These indeterminate lesions are found in 4-
24% of the patients and may lead to several additional examinations, but more than 70% of the 
lesions lack clinical significance29. For the detection of liver metastases, the sensitivity and 
specificity is good (74-84% and 95-96%), but in case of uncertainty, magnetic resonance 
imaging (MRI) is recommended as it has a higher accuracy, particularly in smaller lesions30,31. 
The sensitivity to predict the distance of the rectal tumour to mesorectal fascia (MRF) is 
however low, below 50%, and therefore CT should not be used for local staging32. 
1.1.4.3 Magnetic resonance imaging 
MRI has become an indispensable clinical instrument for the staging and evaluation of rectal 
tumours. A correctly performed high resolution T2-weighted MRI can adequately stage a rectal 
cancer, and thereby facilitate treatment selection. It may identify tumour-related high-risk 
features and is as a reliable instrument for both the selection of patients for neoadjuvant 
treatment and evaluation of the same treatment33-35. MRI allows for an evaluation of tumour 
depth (T-stage), lymph nodal involvement (N-stage), relation to the mesorectal fascia (MRF), 
extramural venous invasion (EMVI) and presence of tumour deposits. The T-staging mainly 
helps at pointing out early, superficial tumours where organ-sparing treatment may be possible 
as well as advanced tumours demanding neoadjuvant treatment34. N-staging is based on the 
number of regional lymph nodes with suspected neoplastic growth. It has been shown that it is 
not the nodal size but rather the nodal shape, with findings of a mixed signal intensity of the 
node combined with an irregular border contour, that predicts a positive pathologic finding36. 
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The MRF represents the surgical resection plane and the relation of the tumour to MRF is an 
important predictive marker of a clear circumferential resection margin (CRM). The accuracy of 
a pelvic MRI in the staging of T-, N-, and CRM-involvement has been manifested in several 
studies37-39. In a meta-analysis by Al-Sukhni et al., including 21 studies, the sensitivity for T-
stage was 87% and for N-stage and CRM-involvement 77% each. The specificity was highest 
for predicting CRM involvement (94%) and somewhat lower for predicting T-stage (75%) and 
N-stage (71%)40. In summary, MRI is regarded to have a very high predictive value in the 
assessment of positive or negative CRM, and a lower but still good value for the prediction of 
lymph node staging. 
MRI interpretation and staging of locally recurrent rectal cancer (LRRC) is more demanding 
than ordinary RC staging. One of the challenges in LRRC is to distinguish tumour regrowth 
from fibrotic scar tissue. Diffusion-weighted imaging has been suggested as a complementary 
tool to facilitate this assessment but is not fully implemented in clinical practice yet41,42.  
 
 
 
1.1.4.4 PET-CT 
In (FDG)PET-CT (Fluorodeoxyglucose Positron Emission Tomography-Computed 
Tomography), the increased metabolism of neoplastic cells is used for the tracing of tumours. A 
radioactive isotope, incorporated with a glucogen (FDG), is injected into the patient, 
metabolised in the tumour cells and detected by the PET-scanner43. The integrated PET-CT 
evaluation provides additional knowledge of the exact anatomic location of the potential 
neoplastic lesion. The method may be useful as a complement to standard preoperative 
assessment, especially for diagnosis of indeterminate, potentially metastatic lesions44. Mucinous 
tumours, however, have a poorer FDG uptake, which is why this type of lesions may be 
missed45. The method may accurately evaluate treatment response after CRT and is a useful tool 
for treatment selection, but is not as reliable for stating a complete response46. 
Figure 3 MRI-scan of patient with 
local recurrence, tumour indicated 
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1.1.5 Pathological staging  
Postoperative pathological staging is important, since it evaluates the surgical quality and 
prognosis and forms the basis for a decision of whether adjuvant treatment should be given. 
Several parallel staging systems are currently used in clinical practice. The previously used 
Dukes’ classification system has today been replaced by the TNM-system, developed by the 
Union for International Cancer Control (UICC) and the American Joint Committee on Cancer 
(AJCC). The three categories T (tumour depth), N (lymph node status) and M (metastasis) are 
evaluated separately and the staging provides the basis for clinical treatment decisions. For 
prognostic calculations, a concluding assessment of the TNM is converted into a numeric stage 
(I-IV). The TNM-system is regularly revised and updated. The currently used 7th edition was 
released in 200947. 
 
Table 1 TNM-classification of colorectal cancer, 7th edition47. 
TNM   
Primary tumour (T) TX 
T0 
Tis 
Primary tumour cannot be assessed 
No evidence of primary tumour 
Carcinoma in situ: intraepithelial or invasion of lamina propria 
 T1 Tumour invades submucosa 
 T2 Tumour invades muscularis propria 
 T3 
T3a 
T3b 
T3c 
T3d 
Tumour invades through the muscularis propria into pericolorectal fat 
Minimal invasion <1mm beyond the borders of the muscularis propria 
Slight invasion 1-5 mm beyond the borders of the muscularis propria 
Moderate invasion 5-15 mm beyond the borders of the muscularis propria 
Extensive invasion >15 mm beyond the borders of the muscularis propria 
 T4a 
T4b 
Tumour penetrates to the surface of visceral peritoneum 
Tumour directly invades or is adherent to other organs and structures 
Regional lymph nodes (N) NX 
N0 
Regional lymph nodes cannot be assessed 
No regional lymph node metastasis 
 N1 
N1a 
N1b 
N1c 
Metastasis in 1-3 regional lymph nodes 
Metastasis in 1 regional lymph node 
Metastasis in 2-3 regional lymph nodes 
Tumour deposit(s) in the subserosa, mesentery or non-peritonealised 
pericolic or perirectal tissues without regional nodal metastases 
 N2 
N2a 
N2b 
Metastasis in 4 or more regional lymph nodes 
Metastasis in 4-6 regional lymph nodes 
Metastasis in 7 or more regional lymph nodes 
Distant metastases (M) MX 
M0 
Distant metastasis cannot be assessed 
No distant metastasis 
 M1 
M1a 
M1b 
Distant metastasis 
Metastasis confined to one organ or site 
Metastasis in more than one organ/site or the peritoneum 
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Table 2 Staging of colorectal cancer, according to the American Joint Committee on Cancer, 
7th edition 
Stage  T N M Dukes’ 
0 Tis N0 M0 - 
I 
I 
T1 
T2 
N0 
N0 
M0 
M0 
A 
A 
IIA 
IIB 
IIC 
T3 
T4a 
T4b 
N0 
N0 
N0 
M0 
M0 
M0 
B 
B 
B 
IIIA 
 
IIIB 
 
 
IIIC 
 
T1-T2 
T1 
T3-T4a 
T2-T3 
T1-T2 
T4a 
T3-T4a 
T4b 
N1/N1c 
N2a 
N1/N1c 
N2a 
N2b 
N2a 
N2b 
N1-N2 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
C 
C 
C 
C 
C 
C 
C 
C 
IVA 
IVB 
any T 
any T 
any N 
any N 
M1a 
M1b 
- 
-  
 
 
 
1.1.6 The Swedish Colorectal Cancer Registry 
The Swedish Colorectal Cancer Registry (SCRCR) is a national registry, founded by the 
National Board of Health and Welfare in 1995 with the intention to monitor management and 
treatment in patients with CRC. Prospective reporting of clinical data of all patients with 
diagnosed adenocarcinomas is mandatory for surgeons, oncologists and pathologists. Diagnoses 
made during autopsy are exempted. Initially, only data on patients with RC were reported, but 
since 2007, the registry also holds data on patients with colon cancer (CC). Up to 2016, 37 000 
patients had been included in the SCRCR and the coverage rate for RC patients is estimated to 
99%1,48. Reported data include patient and tumour characteristics, date of surgery, type of 
surgery, type of neoadjuvant and adjuvant treatment, complications of surgery, resection 
margins, pathologic tumour details, follow-up data at three and five years after primary surgery, 
diagnosis of local recurrence and diagnosis and location of distant metastases49. Data on 
management and treatment of patients with LRRC are not reported. 
The registry has been validated at several occasions49-52. In 1998, the first validation was 
performed, showing a discrepancy of less than 5% concerning the core variables type of 
surgery, tumour stage, postoperative mortality, perioperative perforation and anastomotic 
leakage (AL)49. In another validation, directed specifically towards the complications, it was 
found an adequate reporting of major complications but an underreporting of minor 
complications, i.e. wound infections50. Jörgren et al. agreed on a high validity (<10% 
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discrepancy) of the registry on main variables but that 11% of the LRRC registrations were 
false52. In summary, data have been considered to be of good quality concerning patient, tumour 
and treatment data but there is an underreporting of complications and follow-up data49-51. 
Every person working with data from the SCRCR is encouraged to report any misclassifications 
that are found. This makes the registry a living document, where changes are continuously 
incorporated. Annual reports of SCRCR data are published online and are frequently used for 
the evaluation and improvement of rectal cancer management on both national, regional and 
local (hospital) levels. There is a lively research activity attached to the registry, resulting in 
close to 100 publications up to the present and an additional number of on-going projects53. 
 
 
1.1.7 Multidisciplinary therapy conference  
After completing the preoperative assessment, all patients with CRC should be individually 
discussed at a multidisciplinary team (MDT) conference. In the MDT discussion, details of the 
current tumour are processed together with background data, such as co-morbidity, previous 
treatment, patient’s preference and social situation. Both pre- and postoperative discussions are 
warranted. The team may have different compositions but the participation of surgeon, 
oncologist, pathologist and radiologist is recommended as a minimum54. The meetings not only 
facilitate communication between different disciplines but have also proven to improve both the 
quality of assessment and the outcome of surgery. One study showed a significant reduction in 
the rate of patients operated with a positive CRM after the implementation of preoperative 
MDT meetings and another demonstrated an improved quality of the preoperative assessment 
and staging55,56. In a Swedish population-based study it was shown that the practice of MDT 
conferences combined with an increased staging with MRI more than doubled the rate of R0 
resections57. The routine use of MDT is today implemented in many cancer disciplines 
worldwide58,59.  
Regarding patients with LRRC, few studies of the isolated effect of an MDT have been 
performed. It has however been stated that a multidisciplinary approach is of even greater 
importance in these complex patients, and there is reason to believe that MDT conferences 
facilitates this, particularly through a better selection for surgery60. 
 
 
1.1.8 Neoadjuvant treatment 
Neoadjuvant treatment, also called preoperative treatment, may be given as either RT alone or 
as a combination of chemotherapy and RT, so called chemoradiotherapy (CRT). The purpose of 
RT is either to kill potential tumour cells located close to the tumour itself, or to initiate a 
shrinkage, a so-called downstaging, and thereby convert a large inoperable tumour into a 
smaller, resectable one. The purpose of a combined treatment with CRT is to potentiate the 
effect of RT.  
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Comprehensive research during the last 30 years has led to an increased knowledge about the 
effects of RT in patients with RC and implementation of the results has reduced the rate of 
LRRC significantly61. The Uppsala trial investigated whether RT should to be given pre- or 
postoperatively. 471 patients with stage II and III RC were randomised to preoperative short-
course (5x5 Gy) RT or postoperative long-course (2x30 Gy) RT62. The study showed a lower 
LRRC rate in patients irradiated preoperatively, but there was no difference in survival. In the 
Stockholm I trial, the aim was to compare the oncological results for patients treated with short-
course (5x5 Gy) RT followed by surgery with patients treated with surgery alone. The results 
showed a significantly lower LRRC rate in the RT-group, 16 vs 30%, but a higher risk of early 
postoperative mortality, especially among elderly63. The same tendency was observed in the 
Dutch TME-trial64. Therefore, the Stockholm II and the Swedish Rectal Cancer Trial were 
initiated with an adjusted protocol, in order to lower the postoperative morbidity and mortality 
among RT patients while maintaining the reduced LRRC rate65,66. The goals were achieved and 
an increased cancer-specific survival rate was also seen.  
Despite the improved results, the mortality however remains high and there is reason to believe 
that the survival could be improved if time to surgery is delayed. This hypothesis is being 
explored in the Stockholm III trial and the recently published first results indicated a 
significantly lower risk of postoperative complications after short-course RT with delayed 
surgery compared to the same RT-regime followed by immediate surgery67.  
Finally, a few trials have been performed investigating the value of a combined treatment with 
CRT versus RT alone68,69. The combined regime had the best results in terms of both local 
relapse and survival, particularly for locally advanced tumours. An on-going European 
multicentre clinical trial, RAPIDO, is investigating the possible benefit of preoperative 5x5 Gy 
followed by six cycles of capecitabine/oxaliplatin instead of the standard regime with 
preoperative 1.8 x 25 Gy combined with capecitabine in patients with locally advanced RC70. 
The hypothesis is that the experimental group will have an improved survival and maintained 
local control.  
In summary, based on the results of these trials, an algorithm for neoadjuvant treatment of rectal 
cancer has been established (Table 3)71. A discussion of implementation of delayed surgery in 
the intermediate tumour group, as suggested by the Stockhom III study group, is on-going.  
Given the potency of RT, there are also many side effects, both acute (erythema, nausea, 
cystitis, diarrhoea) and long-term (impaired sphincter function, sexual dysfunction, pelvic 
fractures and ileus)72. An increased risk of secondary pelvic malignancies has been suggested, 
but this could not be seen in a recently published study. In fact, the study showed than men had 
a decreased risk of prostate cancer after previous RT73. An evaluation of each patient’s 
individual pre-existing condition should always be made before treatment and the final decision 
is taken at the MDT conference.  
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Table 3 Radiotherapy recommendations according to tumour classification as described by 
Blomqvist et al.71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.9 Surgical treatment 
1.1.9.1 Total mesorectal excision 
The technique of total mesorectal excision (TME) was first described by RJ Heald in 198274. 
Since his presentation of a five-year LRRC rate of 4% in contrast to 25% in a comparable group 
not operated with TME, several studies have confirmed the good results and the method has 
been successively implemented throughout the world75,76. TME is today regarded as the gold 
standard for surgical treatment of RC77.The method implies an excision of the rectum and the 
complete mesorectum in one piece without interruption, including the main supporting blood 
vessel the inferior mesenteric artery (Figure 4). With this method, all regional lymph nodes, 
including potential tumour growth, are removed, while the important nerve supply of the urethra 
and the external genitals is spared. TME surgery is primarily warranted for resection of tumours 
located in the lower or mid rectum. For high rectal tumours, partial mesorectal excision (PME) 
is sometimes performed instead, but the oncologic safety of this approach is debated78,79. The 
main advantage of PME is that a higher division of the bowel leaves behind a longer spared part 
of the healthy rectum entailing a reduced risk of functional side-effects80. Originally, TME was 
performed thorough laparotomy but minimally-invasive techniques have evolved and a large 
part of rectal resections are today performed by laparoscopy or robot-assisted laparoscopy with 
similar oncologic results81,82.  
 
Favourable ”good” 
tumour 
Mid/upper rectum ≥6 cm 
T1-T3b 
 
Low rectum ≤5 cm 
T1-T2, T3a 
N0 
 
MRF clear 
 
Intermediate ”bad” 
tumour 
Mid/upper rectum 
T3c-d 
 
Low rectum 
T3b-d 
 
T4 with peritoneal/vaginal 
involvement only 
N1-2 
MRF clear 
 
Advanced ”ugly” tumour 
T3 MRF positive 
 
T4 with overgrowth to 
prostate, seminal vesicles, 
base of urinary bladder, 
pelvic side wall or floor, 
sacrum 
 
Positive lateral lymph 
nodes 
 
Primary surgery 
Preop 5x5 Gy with immediate 
primary surgery 
Preop CRT or 5x5 Gy 
with delayed surgery 
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Figure 483. Appropriate planes for total mesorectal excision. A. Anterior view demonstrating 
dissection plane between visceral mesorectal fascia and parietal fascia. B. Lateral view of 
appropriate TME plane in the male. C. Lateral view of TME dissection plane in the female. 
Reprint with permission. 
 
1.1.9.2 Anterior resection 
Anterior resection (AR) is an abdominally performed TME-resection with formation of a direct 
anastomosis. AR is today the preferred and most commonly used method in RC surgery. The 
anastomosis may be performed as a straight pairing (end-to-end), a side-to-end junction or as a 
colon reservoir in shape of a J-pouch. The end-to-end technique has proven to result in worse 
functional results in terms of bowel continence and urgency, while the side-to-end and J-pouch 
methods have had equal, superior results84,85. Out of common postoperative surgical 
complications, the most feared is an anastomotic leak (AL). This occurs in 3-12% of the 
patients and is associated with increased morbidity and, according to some studies, a worse 
oncologic outcome86,87. The role of a temporary diverting ileostomy in lowering the risk and 
consequences of a potential AL has been debated88. In a Swedish randomised trial from 2007, 
RECTODES, 234 patients operated with AR were randomised to either a diverting ileostomy or 
no stoma and the results indicated a three-fold increased risk of AL in the patients without 
stoma and an equally elevated risk of reoperation. The results have been confirmed in 
retrospective studies and construction of a diverting ileostomy in low rectal anastomoses is 
currently recommended in many centres54,89,90. The benefits and risks of a diverting ileostomy is 
however still under discussion91. 
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1.1.9.3 Abdominoperineal resection 
Abdominoperineal resection (APR), also called abdominoperineal excision (APE), is the 
procedure of choice in low rectal tumours (<6 cm from the anal verge), where a sphincter-
preserving surgery cannot be achieved or the functional results are expected to be poor. The 
original procedure was first described by WE Miles in 190892, but has been slightly modified 
since then. An APR is initially performed according to a regular TME procedure. When the 
dissection of the rectum has reached the pelvic floor, the operation is either continued in a 
supine position or the patient is turned into a prone position and the anus, sphincters and anal 
canal are excised from below. The specimen is then removed, the perineal defect is closed and 
an end-colostomy is created. Although Miles’ results indicated a reduction of the rate of LRRC, 
the method is today associated with poorer outcome in terms of local relapse and survival 
compared with a regular TME with direct anastomosis93-95.  
1.1.9.4 Hartmann’s procedure 
Hartmann’s procedure (HA) is an alternative to AR when the preoperative sphincter function is 
weak or the patient’s general condition would not allow for an AL. The procedure includes a 
resection of the rectosigmoid colon with closure of the remaining rectal stump. In RC surgery, 
HA is performed as a TME or PME, but the proximal end of the sigmoid or left colon is led out 
through the abdominal wall as a stoma. The procedure is associated with high morbidity and 
mortality rates, possibly due to the population selected for treatment49,96. In an on-going 
multicentre trial, HAPIRECT, patients with RC where HA is indicated are randomised to either 
ordinary HA or intersphincteric APR. The hypothesis of the trial is that patients operated with 
APR will have a lower rate of local complications and a superior quality of life (QoL)97. 
1.1.9.5 Other types of treatment 
For very early rectal tumours, where the risk of spread to regional lymph nodes is small, 
different techniques for local excision have evolved as an alternative to abdominal surgery98,99. 
The great advantage with a local excision is a lower risk of complications and functional side 
effects, and the procedures may be performed in patients for whom abdominal surgery is 
discouraged. These advantages must of course be weighed against the somewhat elevated risk 
of recurrence, and a thorough selection of well-informed patients is essential. 
An interesting group of patients are those where the neoadjuvant treatment results in a complete 
tumour remission, with an undetectable tumour at follow-up MRI and clinical investigation. An 
intensified surveillance according to the so-called Watch-and-Wait regime, has been suggested 
as an alternative to major abdominal surgery in these selected patients. The results have been 
promising, indicating a low regrowth rate and survival rates corresponding to those expected for 
the corresponding stage100-102. 
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1.1.10 Classification of residual tumour 
The residual tumour classification is an important instrument to evaluate the quality of RC 
surgery and serves as a complement to the regular postoperative TNM-staging. Resection 
margin status is given as R0, R1 or R2 and has a crucial impact on the prognosis103. 
 
Table 4 Residual tumour classification 
Residual tumour  
Rx Residual tumour cannot be assessed 
R0 No residual tumour 
R1 Microscopic residual tumour 
R2 Macroscopic residual tumour 
 
 
1.1.11 Adjuvant treatment 
The purpose of adjuvant chemotherapy (ChT) is to eliminate potential distant micro-metastases 
after tumour resection. The treatment has a well-documented effect in CC, but the results are 
poorer in RC, particularly after performed preoperative RT or CRT104,105. The reasons for this 
are not fully understood, but a delayed start of the adjuvant treatment due to time-consuming 
neoadjuvant treatment has been suggested as one explanation106. The potentially small benefit 
must be viewed in relation to potentially toxic side-effects of the ChT. Adjuvant ChT is today 
only recommended in selected cases and should always be preceded by an informative 
oncologic consultation about the diverging results of a beneficial effect of ChT in RC. 
 
1.1.12 Follow-up 
A number of randomised clinical trials have been performed in order to evaluate the potential 
gains of scheduled follow-up programmes after primary CRC, with varying results107-117. 
Although the frequency of visits and the type of investigations performed differ widely between 
studies, there is sufficient evidence of an increased survival to motivate formalised 
postoperative surveillance111,112,115. The main purpose of the follow-up is to detect early distant 
spread of the disease, mainly to the liver, and secondly, to diagnose a LRRC at a curable stage. 
Other profits are early removal of colorectal adenomas, findings of metachronous neoplasms 
and an improvement of QoL. Due to the different designs and divergent results of previous 
studies, the intensity of the surveillance is however debated and the economic aspects are not 
sufficiently evaluated118. An intensified follow-up during the first two years, when a majority of 
recurrences occur, has been suggested but the evidence for this is still missing. In a recently 
completed multicentre trial, COLOFOL, 2509 patients radically operated for stage II-III 
colorectal cancer have been randomised to either low-frequency follow-up (12 and 36 months 
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after surgery) or high-frequency surveillance (6, 12, 18, 24 and 36 months after surgery). A 
clinical examination, S-CEA and CT of thorax and liver are performed at each visit119. Final 
results from the trial will follow shortly. The current recommendation in the Swedish national 
guidelines for RC corresponds to the low-frequency arm in the COLOFOL trial, with addition 
of a colonoscopy at 36 months postoperatively54. Patients with stage I RC are at low risk of 
distant tumour recurrence and routine imaging is not recommended, although rectoscopy or 
colonoscopy is often performed to rule out the emergence of new adenomas120. 
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1.2 LOCAL RECURRENCE 
 
1.2.1 Incidence 
The rate of LRRC has decreased considerably during the last decades due to an improvement of 
several factors in combination. Optimised preoperative staging, the introduction of TME as the 
preferred surgical method, the addition of preoperative RT to selected patients, an enhanced 
multidisciplinary management and an implementation of follow-up screening programs have 
resulted in a decrease in LRRC rates from 20-40% to 5-9%66,121-126. According to the annual 
report from the SCRCR 2014, five-year follow-up data of patients curatively resected for RC 
between 1995-2009 showed a decrease in LRRC rate from 13% to 5% during the selected time 
period127 (Figure 5). A majority of LRRCs occur within two years after treatment for primary 
RC and more than 90% are diagnosed within five years128,129. RT has been shown to increase 
the disease-free interval and the proportion of LRRC diagnosed after more than two years is 
higher in these patients52,130,131. About 20-40% of the patients with LRRC have distant 
metastases already at the time of diagnosis126,132. 
 
Figure 5 Rate of local recurrence within five years for patients curatively operated for primary 
rectal cancer 1995-2009, illustrated per region127. Reprint with permission. 
 
1.2.2 Risk factors 
1.2.2.1 Stage of primary tumour 
Despite clear resection margins at primary surgery, several studies have suggested that patients 
with a stage III primary RC are at higher risk of LRRC than patients with stage I-II 
tumours52,129,133,134. This may be attributed to the engagement of lymph nodes in stage III 
tumours, which is already an indication of a dissemination of tumour cells. The risk is even 
more pronounced in in case of perineural or endovascular invasion129,134. 
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1.2.2.2 Radiotherapy 
The beneficial oncologic effects of preoperative RT are indisputable61. RT not only reduces the 
rate of LRRC, but also delays the tumour regrowth in those for whom LRRC occurs52,130. Once 
the LRRC has occurred, a worse survival has been seen in previously irradiated patients, 
suggesting a more aggressive type of tumour in these patients126. 
1.2.2.3 Type of primary surgery 
LRRC is more common in patients previously operated with APR, compared to those operated 
with AR93-95. The reasons for this are probably multifactorial. The anatomy below the 
termination of the MRF with only a thin layer of tissue surrounding the bowel, may lead to an 
exposure of the tumour to the CRM and higher rates of positive resection margins135. Analyses 
of bowel specimens after APR have also demonstrated findings of a “waist” at the level of the 
puborectal muscle, resulting in a more narrow resection margin136,137. The inferior results in this 
group of patients have led to the suggestion of an alternative surgical technique, where the 
excisional plane lies outside the external anal sphincter and the levator muscle. There are 
indications that this Extra-Levator Abdominoperineal Excision (ELAPE) may lead to improved 
resection margin status and a reduced LRRC rate, but further studies are warranted138,139. 
1.2.2.4 Resection margins 
A positive CRM is usually pointed out as the most influential risk factor of LRRC140-144, 
although some studies have not found any relation145,146. Tumour involvement of the CRM is an 
important marker of the quality of the surgery and not only increases the risk of LRRC but also 
implicates a higher risk of distant metastases and a worse survival147. 
1.2.2.5 Complications of surgery 
There are divergent results regarding the impact of an AL on the risk of developing a 
LRRC148,149. In a recent review and meta-analysis, it was found that an AL was associated with 
an increased risk of LRRC and a poorer both overall and tumour-specific survival87. A possible 
explanation to this effect is a leakage of bacteria causing an infectious environment, stimulating 
an enhanced proliferation of migrated tumour cells. An increased risk of LRRC has also been 
reported after perioperative bowel perforation and an explanation of dissemination of cancer 
cells has been proposed here as well133. 
 
1.2.3 Definition and diagnosis 
The definition of LRRC varies in the literature, but according to an international consensus 
statement, LRRC may be defined as “recurrence, progression or development of new sites of 
rectal tumour within the pelvis after previous resectional surgery for RC”150. Tumour growth in 
the ovaries is usually regarded as metastatic due to a separate vascular supply, unless it is the 
result of a local overgrowth. A positive tumour biopsy is the first-hand choice for diagnosis, but 
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radiology with MRI or CT combined with an expertise discussion at an MDT conference may 
be sufficient when biopsy is not possible150. 
 
1.2.4 Clinical presentation  
The patient may present with a variety of symptoms, depending on the type of previous surgery 
and involved organ system of the LRRC. Intraluminal tumours in patients with a persistent 
bowel continuity through the lesser pelvis that present with change of bowel habits or rectal 
bleeding, are possibly detected earlier than other recurrences. Patients previously treated with 
APR may have symptoms of micturition disturbance, hematuria, vaginal bleeding, a palpable 
tumour mass or pain. Pain in the perineum, pelvis or legs is a sign of nerve bundle involvement 
and has been shown to be an independent marker of a poor prognosis151,152. Other common 
symptoms are weight loss, fatigue, deep venous thrombosis (DVT) and anaemia. However, a 
number of patients are asymptomatic and diagnosed during planned follow-up visits153. 
 
 
 
1.2.5 Tumour location 
Since an altered anatomy and interrupted surgical planes may prevent clinical staging according 
to the TNM-system, several anatomical classification models are used in current praxis instead. 
According to the American Memorial Sloan Kettering classification, the tumour location is 
categorised in compartments, either axial, anterior, posterior or lateral, where axial tumours are 
located in the bowel and most often originate from the anastomosis154 (Figure 7). It is generally 
assumed that tumours limited to the axial area have the best prognosis and a likelihood of up to 
90% R0-resection has been presented in these patients154,155. An anterior location includes 
tumour growth in the urogenital tract, excluding the ureters, which count as lateral. Tumours in 
the sacrum, coccyx and presacral area are perceived as posterior and a location close to the 
pelvic side wall, the ureter, the piriform and obturator internus muscles, the iliac vessels and the 
Figure 6 Local recurrence located in the 
perineum. (Photo: Torbjörn Holm) 
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lumbosacral plexus are considered lateral. A disadvantage with this system is that it does not 
allow for multiple compartment involvement. 
According to the Leeds classification, all relapses within the lesser pelvis without contact to 
bone are named central. The remaining tumours are classified as either sacral or side wall156 
(Figure 8). The Mayo group describes LRRCs as either sacral, anterior, left or right and also 
involves the extent of fixation151 and Wanebo et al. have presented yet another definition which 
is closely related to the traditional TNM staging system157. Before the introduction of TME and 
preoperative RT, central LRRCs used to be the most common, but a change towards a higher 
proportion of lateral and posteriorly located tumours has been seen in recent years158. Lateral 
recurrences are considered to be the greatest surgical challenge and have the least chance of 
clear surgical resection margins due to the involvement of vital, potentially unresectable 
structures154,159,160. 
 
 
1.2.6 Treatment  
1.2.6.1 General considerations 
As patients with LRRC constitute a heterogeneous group both regarding location and extension 
of the tumour, individual conditions must be taken into account and the MDT-conference is of 
utmost importance57,60. Even a curatively intending treatment may have comprehensive 
consequences for the patient’s future life and an open and informative preoperative consultation 
is important. Neoadjuvant RT should be recommended to patients who have not yet exceeded 
the recommended dose54,150. The current Swedish standard fractionation for locally advanced 
RC is 25-28 x 1.8-2 Gy, but higher doses may be given to patients with LRRC54. In cases with 
Figure 7 Compartments of the small pelvis 
according to the Memorial Sloan Kettering 
classification: axial (red), anterior (purple), 
posterior (orange) and lateral (green) 
 
Figure 8 Compartments of the small pelvis 
according to the Leeds classification: 
central (blue), sacral (orange) and sidewall 
(green) 
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signs of extramural tumour growth, a combined treatment with CRT is normally given. The 
practice of re-irradiation is controversial161. In a systematic review including 10 previous 
reports, it was summarised that re-irradiation is feasible, safe and efficient both for patients 
treated with curative and palliative intent162. The reported toxicity however seems to increase in 
surgically treated patients and when the time interval to previously given RT is short162,163.  
1.2.6.2 Contraindications for surgery 
The absolute contraindications to pelvic resections of LRRC used to be many: peritoneal 
carcinomatosis, high sacral involvement, growth around the external iliac vessels, invasion of 
the sciatic nerve, tumour fixation with bony invasion, bilateral hydronephrosis and presence of 
major leg edema164,165. According to an international consensus statement from the Beyond 
TME Collaborative Group, led by P Tekkis, in 2013, the only absolute contraindications are 
today few; bilateral sciatic nerve involvement, circumferential bone involvement and poor 
performance status or medically unfit patient (i.e. severe cardiopulmonary involvement)150 
(Table 5). Among the relative contraindications, it was pointed out that a resection above the 
S2/3 junction could be performed with suitable surgical expertise and equipment in very 
dedicated centres and that a predicted R2 resection could be performed in rare circumstances 
after MDT agreement. The agreement in the consensus group was high (>90%) for all 
indications except for the indication encasement of external iliac vessels, where it was 
somewhat lower (78%).  
 
Table 5 Absolute and relative contraindications to surgical resection of local recurrence, 
according to the Beyond TME Collaborative group150. 
Absolute contraindications Relative contraindications 
Bilateral sciatic nerve involvement Extension of tumour through the sciatic notch 
Circumferential bone involvement High sacral involvement 
Poor performance status/medically unfit 
patient 
Encasement of external iliac vessels – 
requiring en bloc resection and/or 
reconstruction of external iliac vessels 
 Irresectable distant metastases 
 Predicted R2 resection 
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1.2.6.3 Central recurrences 
For axial recurrences limited to the anastomosis or the perineum, an APR of the neorectum is 
generally the preferred surgical method, while a proximity to or involvement of the 
genitourinary organs usually require a total pelvic exenteration (PE)166. 
PE was at the time of introduction by A Brunschwig in the late 1940s described as “the most 
radical surgical attack so far described for pelvic cancer”167. It was initially performed for 
palliative purposes only, but as results improved, it has turned into the preferred surgical 
method for potential cure of advanced pelvic tumour growth156,159,167,168. A varying 
nomenclature exists, where distinctions of anterior, posterior, supralevator, total, extended or 
individualised approaches are found, depending on the compartment(s) resected165,169. A total 
PE however implies a complete resection of the pelvic viscera, including the rectum, urinary 
bladder, reproductive organs, pelvic peritoneum and perineum en bloc, with following 
reconstruction of bowel, perineum and urinary tract165,170.  
The procedure is technically demanding and is recommended to be performed only in centres 
with high operation volumes and an engaged MDT171. In a recent meta-analysis covering 30 
studies reporting results after PE for locally advanced RC between 1998-2014, negative 
resection margins (R0) were reported in 66% (range 32-100%) of the included patients with a 
LRRC. The overall survival was directly related to margin status, with a nearly three-fold risk 
of death after R1-resection (HR 2.74, 95% CI 1.29-5.79)172.  
 
 
 
1.2.6.4 Posterior recurrences 
Posteriorly and laterally located tumours represent a special challenge in the surgery of LRRC 
and extended exenterations are sometimes needed in these patients. In a recent review, seven 
studies of in total 220 patients operated with PE with en bloc sacrectomy were included. R0 
resection was achieved in 78% of the patients and a 55% disease-free survival after a median of 
Figure 9 Specimen after en bloc 
resection of bowel, prostate and urinary 
bladder (Photo: Torbjörn Holm) 
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33 months of follow-up was seen taken all studies together173. All studies were performed in 
highly dedicated centres. A major problem in this type of surgery is the risk of haemorrhage, 
due to a rich vascular supply. Sacrectomy is considered to be safe below the S2/S3 junction and 
pelvic stabilisation is usually not needed. Resections at the S1/S2 level are performed in a few 
dedicated centres, but this type of surgery entails a higher morbidity, particularly through 
neurologic impact on urogenital function and pelvic instability166.  
1.2.6.5 Lateral recurrences 
Surgery of lateral recurrences is considered to be the most challenging due to potential tumour 
involvement of large nerves, blood vessels and bony stuctures. Austin et al. have described a 
method for the resection of tumours with pelvic wall involvement, including resection of the 
iliac vessels with graft reconstruction174. With this method, the anatomic plane between the 
bony pelvis and the sidewall musculature is used for dissection.  The authors present a series of 
36 performed procedures over a ten-year period. Surgeons from up to five different disciplines 
participated in the operations and R0 resection margins were achieved in 53% of the patients 
with no (0%) intraoperative mortality. In another study, reported from Yamada et al., none (0) 
of the 17 patients that were resected for a lateral LRRC survived five years160. The lack of larger 
reported series regarding this type of highly specialised surgery however probably reflects the 
complexity of the procedure. 
 
 
  
IAA 
PM 
L5 
S1 
S2 
SL 
ON 
Figure 10 Anatomy after clearance of lateral pelvic wall; ON=obturator nerve, L5-S2=left 
sacral nerve roots, IAA=internal iliac artery (ligated), PM=piriform muscle, SL=sacrospinal 
ligament (Photo: Henrik Iversen) 
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1.2.6.6 Reconstructions 
Extensive pelvic resections require reconstructions of bowel, perineum, urinary and genital 
tracts. Apart from the more obvious construction of a colostomy from the sigmoid colon or an 
anastomosis re-implanting the urether into the urinary bladder, more specific procedures may be 
needed. E Bricker described a technique for reconstruction of the urinary bladder by an ileal 
conduit175. The Bricker deviation is today the most widely implemented method for urinary 
diversion after PE. Continent urinary diversion techniques exist but are generally avoided in 
these severely ill patients due to higher complication rates176.  
For low extensively growing tumours demanding ELAPE, a larger defect is left in the perineum 
compared with standard APR138. In order to reduce the risk of infections and improve wound 
healing, a variety of myocutaneous flap procedures have been presented, where the rectus 
abdominis, the gracilis or the gluteus maximus muscles are harvested from their original sites 
and rotated into the perineal defect, where they are attached177-180. Previously presented case 
series are small, and long-term follow-up data are often missing. Cibula et al. presented a study 
where the results of 16 patients having a rectus abdominis flap after PE were compared with 24 
patients having PE without a flap. There was a significantly higher rate of complications (79 vs 
44%, p=0.041) and worse performance status after six months among the non-flap operated 
patients181. The largest series was presented by Anderin et al., including 65 patients 
reconstructed with a gluteus maximus flap after ELAPE. Minor perineal wound infections 
occurred in 23% of the patients and more severe infections in 18%. However, after 12 months, 
the gluteal flap was completely healed in 91% of the patients. The authors argue that a gluteus 
maximus flap has an advantage above the rectus abdominis flap, as the wound is located on a 
wider distance from the stoma, minimizing the risk of infections182. New models with biologic 
mesh implants have been tested and a recent review showed a significant reduction of the 
perineal hernia rate compared with both gluteal flap surgery and primary closure, but no 
reduction of the perineal wound infection rate183.  
1.2.6.7 Intraoperative radiotherapy 
The main advantage of intraoperative RT (IORT), in contrast to traditional pre- or postoperative 
external beam RT, is that it allows for a focused delivery of radiation on a limited target, 
without risking to include surrounding organs in the radiation field184. The target is usually a 
resection area where there is doubt about complete clearance of the tumour. Doses varying 
between 7.5 and 30 Gy are delivered intra-abdominally during surgery in patients with or 
without previous RT185. Peripheral neuropathy is the main toxicity after IORT, reported in 5-
14% of the patients in a study from the Mayo Clinic186. Although invented already in the early 
20th century, the first report of modern megavoltage IORT was not published until the early 
1980s, presenting a series of 717 Japanese patients treated for various malignancies187,188. Since 
then, a number of reports of IORT in locally advanced RC or LRRC have been published with 
varying results189-192. The main problem of the studies is the lack of randomised controlled trials 
(RCT) and a wide range of doses and treatment protocols. The only reported randomised trial in 
the literature included 142 patients with locally advanced RC, who all received neoadjuvant RT, 
40 Gy, and then were randomised to either surgical resection only or combined surgical 
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resection and IORT 18 Gy. After five years, there were no significant differences in LRRC rate, 
overall survival, disease-specific survival or distant metastases193. In Sweden, IORT facilities 
are available in two centres, Stockholm/Karolinska and Malmö/Lund. Due to the lack of 
convincing positive study results, the number of treated patients is declining, and IORT is today 
reserved only for selected cases54.  
 
1.2.7 Complications of surgery 
Surgery for LRRC has a high risk of complications both in the short and long term and the 
complication pattern differs depending on the type of surgery performed. Reported early 
complications following AR or APR are wound infection, wound dehiscence, intraabdominal 
abscess, AL, ileus, haemorrhage, DVT, pulmonary embolism, cardiac and renal failure and 
death. In patients operated with APR, perineal wound complications are common and a delayed 
healing of the perineal wound is reported in up to 24% of the patients194,195. The complication 
risk is increased after previous RT in both patients treated with AR and APR195,196.  
In a review analysis of patients operated with PE, the complication rate varied between 37 and 
100% and the median perioperative mortality was 2.2%197. The complication rate is higher in 
these patients compared with those with more limited surgical procedures156. Urinary 
anastomotic leaks after cystectomy may pose a special problem. Teixeira et al. reported a 12% 
risk of urinary leak and the risk was higher (27%) after resection comprising all four 
compartments198.The Clavien-Dindo classification system is often used to quantify 
complications after surgery, relying on a staging of the severity of each complication according 
to a four-graded scale199. Other methods to define complications however also exist. Reported 
long-term complications are anal incontinence after AR, bowel dysfunction, micturition 
disorder, sexual dysfunction, fistulas, pelvic fractures and bowel obstructions. The severity is 
potentiated after previous RT200,201. 
 
1.2.8 Re-recurrence 
A re-recurrence may appear after curative surgery for LRRC and reported rates vary between 4-
54%202. Most of the patients have also developed distant metastases203. The actual number of 
patients who experience a re-recurrence is however small, studies are missing and no specific 
treatment recommendations exist. A history of multiple pelvic resections infers that a curatively 
intending treatment only may be applicable under exceptional circumstances.  
 
1.2.9 Distant metastases 
Distant metastases constitute a common and feared consequence of CRC, since they are the 
direct cause of death in a majority of the patients. About 15-25% of the patients have 
synchronous distant metastases already at the time of primary diagnosis204-207 and another 20-
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25% will develop metastases during follow-up after curative surgery208-211. The most common 
metastatic sites are the liver (40-60%) and the lungs (10-20%)211-213, but tumours may also 
occur in the peritoneum, ovaries, brain, skeleton and lymph nodes209,210. 
The view on treatment of distant metastases deriving from CRC has undergone a dramatic 
change in recent years, especially for liver metastases. From being a definite contraindication to 
curatively intending surgery, up to 25% of the patients with liver metastases are today treated 
with metastatic resection, with a reported five-year survival of 30-50%214-217. The patients are 
routinely discussed at CRC MDT-conferences and preferably also at a specific liver conference. 
The MRI findings are of major importance for the decision of further treatment. Conversion 
therapy with ChT is generally given preoperatively in order to shrink the tumour(s) and 
resection is performed prior to, simultaneously to or after the resection of the primary tumour, 
depending on patient-related factors, location, type of neoadjuvant treatment and which 
procedure is expected to be the most complicated207.  
In a Danish population-based study by Nordholm-Carstensen et al., 3.8% of the patients with 
pulmonary CRC metastases underwent metastatic resection, leading to an increased overall 
survival218. The study also reported a significant association between the rate of pulmonary 
metastases and site of the primary tumour. This has been confirmed in other studies and it 
appears that RC patients are more prone to get pulmonary metastases than CC patients, possibly 
due to a different metastatic pathway through extraportal venous drainage of the 
rectum212,218,219. 
 
1.2.10 Palliative treatment 
According to the World Health Organisation (WHO) definition, palliative care is “an approach 
that improves the quality of life of patients and their families facing the problem associated with 
life-threatening illness, through the prevention and relief of suffering…”220. In other words, the 
contents of a palliative treatment ranges from analgesics or sedatives only to surgical and 
oncologic tumour-specific measures. In an early, pre-symptomatic stage of the disease, the 
palliative treatment aims at prolonging life and preventing symptoms, whereas in already 
symptomatic patients, the goal is to reduce symptoms and improve QoL.  
Miner et al. performed a prospective analysis of more than 1000 palliative surgical procedures 
for in all 25 different malignancies. The results revealed an improvement of symptoms in 80% 
of the patients, but symptoms recurred within less than 2 months in 50% of the patients221. In 
another study, the same author investigated the results of palliative procedures in 105 patients 
with LRRC. 23% of the patients were operated with palliative intent due to different symptoms. 
The largest improvement was seen in patients with obstructive symptoms (70%), followed by 
bleeding (40%) and pain (20%)222. Extensive surgical procedures are however discouraged in 
palliative situations and pelvic exenteration is generally contraindicated223. 
RT has well-documented analgesic effects against symptoms deriving from bone 
metastases224,225. Regarding intrapelvic recurrences, RT may reduce both local symptoms of 
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pain, obstruction and bleeding and the treatment is recommended for palliative treatment of RC 
in the Swedish national guidelines54. ChT is normally recommended at an asymptomatic, life-
prolonging stage, since the patient’s general condition must not be too marked by the disease. 
Ito et al. however evaluated the effect of CRT versus RT alone on pain in patients with LRRC 
and found a significantly longer duration of pain relief (p=0.019) in patients treated with CRT 
(median 7.8 months) compared with RT (median 4.0 months) and a significantly prolonged 
survival (p=0.046)226. CRT may be relevant under certain circumstances, particularly when a 
curatively intending treatment has not been entirely ruled out. 
 
1.2.11 Survival  
Survival data after curatively intending treatment of LRRC vary widely between studies. A 
variety of factors, including tumour location, type of surgery, resection margins and presence or 
absence of distant metastases may affect the results. A report from five pelvic recurrence 
specialist institutions including 533 LRRC patients treated with tumour resection, revealed a 
28% five-year overall survival and a 37% cancer-specific survival for all included patients and 
44% five-year survival for R0 resected patients203. However, more than 50% of the included 
patients had a posterior or a lateral location of the LRRC. In contrast, a Norwegian population-
based study including all patients with diagnosed LRRC in Norway reported five-year survival 
rates of 55% for R0 resected patients, but the corresponding value for all patients was low, only 
15%227. From other studies, five-year survival rates of up to 70% have been reported after R0 
resection and a rate below 10% disregarding treatment or not124,228-232. A curative resection is 
the only chance for tumour-free survival in patients with LRRC. 
 
1.2.12 Quality of life 
An increasing interest for QoL aspects in patients with LRRC has evolved with the 
improvement of surgical techniques. Considering the poor diagnosis and high morbidity risk of 
extensive surgery, it is obvious that many aspects of life will be affected.  
There are several tests to quantify QoL aspects, of which EORTC-QLQ C30, FACT-C and SF-
36 are the most commonly used233-235. All studies evaluate physical, emotional, social and 
cognitive functioning in different ways and the two latter also evaluate symptoms. In one of the 
first studies reporting QoL in patients with LRRC, patients with a manifest LRRC were 
compared with matched patients without evidence of recurrence. The study showed that the 
QoL scores were significantly lower among the LRRC patients regarding all aspects from 
emotional, physical and social functions to gastrointestinal problems, insomnia and appetite236. 
Several studies have however shown an increasing QoL after curative resection of the LRRC, 
but unchanged or even worse values if a complete tumour resection is not acheived237-240.  
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2 AIMS OF THE THESIS 
 
Overall aim 
The overall aim of the thesis was to gain more knowledge about the characteristics, 
management and outcome of patients with LRRC in Sweden. 
 
Specific aims 
Paper I 
To investigate whether the time interval between primary surgery for RC and the time of 
diagnosis of LRRC had any impact on survival after the LRRC diagnosis 
Paper II 
To assess whether factors related to the patient, the primary tumour or the LRRC may predict 
treatment intention with curative or palliative intent 
Paper III 
To investigate potential differences in treatment intention in relation to geographical region or 
time period and to assess outcome and prognosis in patients with LRRC 
Paper IV 
To evaluate surgical treatment of patients with LRRC treated with and without tumour resection 
and to explore complications and prognosis after surgery 
  
 28 
 
 
 29 
 
3 PATIENTS AND METHODS 
 
3.1 PAPER I 
3.1.1 Study population 
All patients operated with surgically radical (R0-R1) abdominal surgery for primary RC 
between January 1st 1995 and December 31st 2002 and with a reported diagnosis of LRRC to 
the SCRCR were identified in the registry. Patients with reported distant metastases prior to or 
simultaneously to the date of diagnosis of LRRC were excluded. Access of data was made on 
March 23rd 2010. 
 
3.1.2 Method – data collection 
Identification of the patients was made through the personal identification number that is unique 
for each Swedish citizen. Information about the patient (sex, age), characteristics and treatment 
of the primary tumour (T-stage, N-stage, Dukes’ stage, tumour height, RT, type of primary 
surgery, date of LRRC diagnosis and follow-up data, including death date and date of last 
follow-up) were extracted and processed. Data concerning resection of the LRRC were not 
available in the registry and information concerning this variable was accesssed from medical 
records that were collected from the hospitals concerned (see further description of the process 
in the method section for paper II-IV).  
The time from date of primary surgery for RC to date of diagnosis of the LRRC was calculated 
and the patients were divided into two groups; those with an early LRRC (ELR), diagnosed <12 
months after primary surgery and those with a late LRRC (LLR), diagnosed ≥12 months after 
primary surgery.  
 
3.1.3 Statistics  
Statistical analyses were performed using Stata®12 (StataCorp, TX, USA). The relationship 
between the dichotomised variable time to local recurrence and categorical variables (sex, type 
of surgery, RT) was tested using the chi-square test of independence, while the relationship with 
ordinal variables (age, tumour height, stage) was tested using the chi-square test for trend. 
When analysing time as a continuous variable as in difference in time to LRRC in irradiated and 
non-irradiated patients, the Mann-Whitney test was used.  
In the survival analysis, end of follow-up was set to April 30th, 2009. Survival was estimated 
using the Kaplan-Meier method and the effect of clinical variables on risk of death was 
calculated with Cox proportional hazards regression. The results of the Cox regression analysis 
were presented as Hazard ratios (HR), where the risk of death for each value of a variable was 
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compared with the reference value of the same variable. Each HR-value was complemented 
with a 95% confidence interval (CI) and a p-value calculated with Wald’s test. A stepwise 
selection procedure using backward elimination was applied to identify the clinical variables 
with the strongest independence. All factors were included in the stepwise model and the 
replication stability was assessed with a bootstrap resampling procedure, as proposed by 
Sauerbrei et al241. 
 
Figure 11 Flow-chart of the selection of patients of study I 
 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Primary surgery for rectal cancer 
1995-2002 
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Radical primary surgery 
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Local or distant recurrence 
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Local recurrence as first event 
Study population 
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Non-radical primary surgery 
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No evidence of recurrence 
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Distant recurrence as first 
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Early local recurrence 
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n=95 
Late local recurrence 
≥12 months after 
primary surgery 
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3.2 PAPER II-IV 
3.2.1 Study population 
In similarity with paper I, all patients abdominally operated for primary RC between January 1st 
1995 and December 31st 2002 and with a diagnosis of LRRC reported to the SCRCR were 
eligible. In contrast to paper I, no selection based on outcome of the primary surgery was made 
on this stage and patients with a diagnosis of distant metastases within 3 months before 
diagnosis of the LRRC were also included in the registry output. In total, 730 patients fulfilling 
the inclusion criteria mentioned above were identified in the SCRCR and a data output on these 
patients was created on March 23rd 2010. 
 
3.2.2 Method – data collection 
Medical records covering the time from primary surgery of RC to date of last visit after 
treatment of LRRC were collected from the 76 different Swedish hospitals responsible for the 
730 identified patients. During the main part of the time studied, the hospitals did not have 
computerised systems for medical records and most of them were kept in archives. Letters were 
sent to both the head of the surgical department of each hospital and to the archives were the 
medical records were held, asking for permission and help with copying and shipping of the 
material. All hospitals agreed to share their medical records. Three hospitals in the Stockholm 
region (Karolinska University Hospital, Danderyd hospital and Ersta hospital) were visited and 
the collection of data was made on site. All collection, reading and interpretation of the medical 
records was made by the author of this thesis. 
The medical records were studied according to a specific protocol, where both information 
already reported to the registry, such as patient and primary tumour data, and “new” information 
concerning the LRRC, was noted. Regarding the patient and primary tumour, information about 
date of birth, sex, hospital, tumour height, neoadjuvant treatement, type of surgery, resection 
margin, pathological TNM-stage, Dukes’ stage, adjuvant treatment and postoperative 
complications was collected. Furthermore, information about the LRRC concerning symptoms, 
diagnosis, preoperative assessment, discussion at MDT conference, treatment intention, 
neoadjuvant treatment, type of surgical treatment, early and late postoperative complications, 
resection margins, type of palliative treatment, presence and type of distant metastases, re-
recurrence and follow-up data was compiled. The information was inserted in a data file that 
was merged with the registry output file, keeping all variables from both the registry and the 
medical records intact in the same file. From this point, all used data were taken from variables 
based on information from the medical records, apart from date of diagnosis of the LRRC and 
date of death, which was taken from the registry. 
Medical records of 32 patients could not be found or lacked essential information. After putting 
the file together, some exclusions of patients were made. Patients with a diagnosis of distant 
metastases before or simultaneously to the LRRC, patients with a surgically non-radical (R2) 
primary surgery and patients without radiology or pathology confirming the diagnosis of LRRC 
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were excluded. Other reasons for exclusion included local excision or unclear resection margins 
at primary surgery, primary surgery outside the time interval 1995-2002, tumour level above 15 
cm and anal cancer. After exclusion, 426 patients remained and they constituted the study 
cohort in paper II, III and IV (Figure 12). 
 
Figure 12 Flow-chart of the selection of patients of study II-IV, step 1 
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Figure 13 Flow-chart of the selection of patients of study II-IV, step 2. Brown colour represents 
groups used in paper II and III. Green colour represents groups used in paper IV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.3 Method – definitions 
The definition of LRRC used in the studies was a regrowth of tumour in the lesser pelvis after 
previous radical (R0-R1) abdominal surgery for primary RC and a diagnosis of LRRC reported 
to the SCRCR. The diagnosis should have been stated by a radiologist or a pathologist. Indirect 
findings of a LRRC, such as a hydronephrosis, were not sufficient for diagnosis. Tumour 
growth in the ovaries was regarded as metastatic unless it was the result of direct overgrowth. 
The location of the LRRC was defined as axial, anterior, posterior or lateral, according to the 
Memorial Sloan-Kettering classification154. Axial tumours included a location at the 
anastomotic site or in the perineum, anterior tumours were located in the internal genitals 
(uterus, vagina, prostate, seminal vesicles) or the anterior urinary tract (urinary bladder, 
urethra), posterior tumours had a location in the sacrum, coccyx or the presacral region, while 
Local recurrence as first event 
n=426 
Treatment with curative intent 
n=149 
Treatment with palliative intent 
n=277 
Treatment with tumour resection 
n=149 
Treatment without tumour resection 
n=193 
Surgical treatment 
n=79 
No surgery 
n=114 
Best supportive care 
n=84 
n=121 n=28 
n=28 n=165 
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lateral tumours were located in the lateral pelvic wall, ureter, internal obturator muscle, iliac 
vessels and lumbosacral plexus. The different sites were thereafter grouped into two 
compartments, with central recurrences, including those with an axial and/or anterior 
involvement only in one and posterolateral recurrences, including those with a posterior and/or 
lateral involvement only in another group. Tumours with involvement of both central and 
posterolateral compartments were named multifocal and tumours in which the location could 
not be determined were named unspecified. All tumours with posterolateral, multifocal or 
unspecified location were thereafter named non-central. 
Co-morbidity was defined as a documented diagnosis of cardiovascular disease (hypertonia, 
ischemic heart disease, heart failure, atrial fibrillation, stroke), neurologic disease (dementia, 
depression, psychosis), respiratory disease (asthma, chronic obstructive pulmonary disease), 
diabetes, previous or synchronous cancer other than rectal cancer or other conditions (renal 
failure, liver failure, HIV, hepatitis) at time of diagnosis of LRRC. 
Postoperative complications were documented according to diagnosis in the medical records. 
No rating of the severity of the conditions was made.  
The administration of Swedish cancer care is organised in six geographical regions, with one 
University Hospital per region. All regions follow the same national treatment programme, but 
with different implementations according to the structure and resources of each region. For the 
analyses in paper III, the regions were randomly named region 1, 2, 3, 4, 5 and 6. 
 
3.2.4 Method – analysed groups  
3.2.4.1 Paper II 
In paper II, the patients were divided into two groups, based on the initial treatment intention of 
the LRRC. 149 patients were treated with curative intent and the remaining 277 patients, 
consisting of both patients treated with oncologic palliative treatment and those only receiving 
best supportive care (BSC), were put together in a group named treatment with palliative intent 
(Figure 13). 
3.2.4.2 Paper III 
In paper III, the patients were analysed according to treatment intention, as described in paper 
II, region and time period. Resection margin status was analysed for patients treated with 
tumour resection with curative intent. In two of the analyses, the patients were analysed 
according to the geographical region where they had been assessed for their LRRC. 
For the analysis of changes over time, the material was divided into three time periods that were 
comparable in length, based on the year of diagnosis of the LRRC. The periods were set to: 
period 1: 1995-1998, period 2: 1999-2002 and period 3: 2003-2007. 
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3.2.4.3 Paper IV 
In this study, the patients were analysed according to the type of performed treatment of the 
LRRC. Patients where a surgical resection of the LRRC had been performed, disregarding 
treatment intention, were analysed as the “treatment with tumour resection” group, while 
patients receiving surgical or oncologic treatment, disregarding treatment intention, but where 
tumor resection had not been performed, were analysed as the “treatment without tumour 
resection” group. The patients who had not received any specific surgical or oncologic 
treatment were analysed as the “best supportive care” group (Figure 13). A tumour resection 
was defined as a removal of all or part of the LRRC, either by an abdominal or a local resection 
procedure. 
 
3.2.5 Statistics  
3.2.5.1 Paper II 
As for paper I, the statistical analyses in paper II, III and IV were carried out using Stata® 12 
(StataCorp, TX, USA). All statistical tests were two-sided and statistical significance was set at 
α=0.05 in all papers. Logistic regression was used to calculate the association between clinical 
factors and treatment intention and the results were expressed as Odds Ratios (OR) for 
treatment with palliative intent compared with treatment with curative intent, complemented 
with a 95% CI. P-values were calculated with Wald’s test. Survival was calculated from time of 
diagnosis of the LRRC to date of death or date of last recorded follow-up. Median follow-up 
time was calculated with the reversed Kaplan-Meier method as described by Schemper and 
Smith242. The Kaplan-Meier method was used to graphically illustrate survival for patients 
treated with curative and palliative intent and to illustrate survival according to time to local 
recurrence, age, presence of symptoms, hydronephrosis and LRRC location in patients treated 
with curative intent. Differences in survival were tested using the log-rank test. The Cox 
regression model was used to estimate HR of death by any cause and was supplemented with a 
95% CI. The proportionality of the Hazard functions was visually inspected and tested with 
Shoenfeld’s residuals243.  
3.2.5.2 Paper III 
In this study, logistic regression was used to assess the association of time period of diagnosis of 
LRRC and geographical region to treatment intention. The results were expressed as unadjusted 
and adjusted (for age at diagnosis, sex and LRRC location) ORs for treatment with curative 
intent. Unadjusted logistic regression was also performed for estimation of the association 
between time period, region and location to resection margins and given values represent the 
OR for a non-radical (R1/R2) resection. As in paper II, the Cox proportional Hazards regression 
was used to estimate risk of failure, in this study including re-recurrence, distant metastases or 
death by any cause. Cumulative incidence functions were used to graphically illustrate failure 
patterns, estimating the probability of re-recurrence, distant metastases or death as first failure. 
Time to failure was calculated from date of surgery of the LRRC. 
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3.2.5.3 Paper IV 
A chi2-test was used to assess the association between clinical variables and performed 
treatment with tumour resection, treatment without tumour resection or best supportive care. 
The results were expressed as p-values. Kaplan-Meier plots were used to illustrate overall 
survival for the four different treatment groups (curative resection, non-curative resection, 
treatment without resection and BSC) and differences in survival were tested with the log-rank 
test.  The same methods were applied to illustrate survival in resected patients with or without 
complications. 
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4 RESULTS 
 
4.1 PAPER I 
4.1.1 Patient and primary tumour characteristics 
According to data from the SCRCR, 9192 patients were abdominally resected for primary RC 
during the period 1995-2002. Of these, 386 patients had a diagnosis of LRRC as first and 
isolated event reported to the registry. Median follow-up time for all patients was 8.6 (range 
2.1-13.8) years from date of primary surgery. The median time to local recurrence was 1.7 
(range 0.1-7.9) years.  
 
4.1.2 Early and late local recurrence 
In all, 95 patients (25%) had an ELR and 291 patients (75%) had an LLR. There were no 
significant differences between the groups regarding age, sex, tumour height or type of primary 
surgery (Table 6). Tumour stage was significantly associated with time to LRRC in a test for 
trend, with a higher proportion of stage III tumours and a lower proportion of stage I tumours in 
the ELR group compared with the LLR group. This difference remained in a multivariable 
analysis with a close to three-fold increased risk of an ELR among stage III tumours (OR 2.74, 
95% CI: 1.1-7.0). Previous RT was significantly more common in the LLR group, both in uni- 
and multivariable analyses. The median time to LRRC was 2.0 years among the irradiated 
patients and 1.5 years among patients treated with surgery alone (p=0.004) (Figure 14). There 
was no significant difference in the proportion of patients treated with tumour resection for their 
LRRC between the groups ELR and LLR (38% vs 32%, p=0.35).  
 
4.1.3 Survival  
Median survival was 1.2 years for all patients, 1.1 years for ELR patients and 1.3 years for LLR 
patients. The difference in survival between patients with ELR and LLR was not significant 
(p=0.53) (Figure 15). Factors with a significant influence on survival in both uni- and 
multivariable analyses were age at diagnosis of the LRRC, stage of the primary tumour and 
performed resection of the LRRC. Patients with a stage III primary tumour had a worse 
prognosis than patients with a stage I-II tumour (HR 1.3, 95% CI: 1.0-1.6). Age and resection of 
the LRRC were the most important prognostic factors in the study, where older patients had a 
worse survival (HR 1.9, 95% CI: 1.3-2.7) and resected patients had a better survival (HR 0.4, 
95% CI: 0.3-0.5) in a stepwise model. In an additional analysis, a stratification on the variable 
resection of the LRRC was performed. In resected patients, the risk of death was increased in 
patients with stage III primary tumour (HR 1.6, 95% CI:1.1-2.4) previously performed APR 
(HR 1.9, 95% CI:1.2-3.0) or HA (HR 2.2, 95% CI:1.1-4.4). On the contrary, in patients without 
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resection of their LRRC, age and sex were the only factors with significant influence on 
survival. Older patients (≥80 years) had an increased risk of death compared with younger (HR 
1.0, 95% CI:1.2-3.0) and female patients had a decreased risk of death compared with male (HR 
0.7, 95% CI:0.5-1.0) in a stepwise model. Time to local recurrence had no prognostic influence 
in neither resected nor non-resected patients. 
 
Table 6 Patient and primary tumour characteristics in patients with early and late LRRC. 
 
 
 aAge at operation of primary tumour. †Chi-square test of independence. ‡Chi-square test for trend. #Missing data not 
included in test.
  
Early local recurrence 
<12 months 
 (n=95) 
 
Late local recurrence 
≥12 months  
(n=291) 
 
 
 
P-value†,# 
 Agea, years 
    <60 
    60-69 
    70-79 
    ≥80 
 Median age, [min-max] 
 
21 (22) 
25 (26) 
28 (30) 
21 (22) 
71 [32-90] 
 
39 (13) 
78 (27) 
105 (36) 
69 (24) 
72 [31-91] 
 
 
 
 
0.20‡ 
 
 Sex 
    Male 
    Female 
 
61 (64) 
34 (36) 
 
160 (55) 
131 (45) 
 
 
0.12 
Primary tumour 
 Tumour height 
    0-5 cm 
    6-10 cm 
    11-15 cm 
Missing 
 
 
24 (25) 
43 (45) 
26 (27) 
2 (2) 
 
 
112 (39) 
95 (33) 
78 (27) 
6 (2) 
 
 
 
 
0.16‡ 
 
 Stage 
    I 
    II 
    III 
 Missing 
 
7 (7) 
31 (33) 
56 (59) 
1 (1) 
 
47 (16) 
103 (35) 
139 (48) 
2 (1) 
 
 
 
0.023‡ 
 Type of surgery 
    AR 
    APR 
    HA 
 
58 (61) 
25 (26) 
12 (13) 
 
164 (56) 
95 (33) 
32 (11) 
 
 
 
0.52 
 Radiotherapy 
    No 
    Yes 
 Missing 
 
58 (61) 
33 (35) 
4 (4) 
 
139 (48) 
138 (47) 
20 (6) 
 
 
0.029 
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Figure 14 Time to local recurrence in non-irradiated and irradiated patients 
 
 
Figure 15 Overall survival in patients with early and late local recurrence 
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4.2 PAPER II 
 
4.2.1 Patient, primary tumour and LRRC characteristics 
Characteristics of all included patients are presented in Table 7 and 8. Median time from 
primary surgery to diagnosis of LRRC was 1.7 (range 0.05-7.9) years and median age at the 
time of diagnosis of LRRC was 74 (range 31-93) years. A majority of the patients (50.9%) had 
been operated with anterior resection (AR) at the time of primary surgery and a majority of the 
patients (55.6%) had stage III primary tumours. In all, 325 patients (76.3%) were operated with 
clear resection margins (R0) at primary surgery.  
Symptoms were present in 360 (84.5%) of the patients at time of diagnosis of LRRC. The most 
common symptom was pain, present in 130 (30.5%) of the patients, followed by anal or 
perianal symptoms (103 patients), change of bowel habits (77 patients), urogenital symptoms 
(67 patients), reduced general condition (30 patients), a palpable tumour (24 patients), and 
lower limb symptoms (16 patients). Regarding location of the LRRC, it was classified as central 
in 213 patients (50.0%), of which it was axial only in 150 patients, anterior only in 29 patients 
and 34 patients had a combination of the two locations. Another 65 patients (15.3%) had a 
posterolateral location, where the LRRC was posterior only in 41 patients, lateral only in 16 and 
8 patients had a combined posterolateral location. 123 patients (28.9%) had a combination of 
central and posterolateral locations and in 25 patients (5.9%), the tumour location was not 
specified.  
 
4.2.2 Predictors of treatment intention 
In all, 149 patients (35.0%) received treatment with curative intent and 277 patients (65.0%) 
were treated with palliative intent. Regarding primary tumour related factors, the risk of 
treatment with palliative intent was significantly increased in patients aged ≥80 years at time of 
primary surgery (OR 3.59, 95% CI: 1.73-7.45), after a performed APR at primary surgery (OR 
5.16, 95% CI: 2.97-8.97) or a performed HA (OR 2.81, 95% CI: 1.40-5.60) or a stage III 
primary tumour (OR 3.43, 95% CI: 1.75-6.72). Investigated factors without association to 
treatment intention were sex, tumour height, neoadjuvant treatment, pT-stage, postoperative 
complications, reoperation within 30 days and margin status. Tumour height, T-stage and 
margin status had a significant association to treatment intention in a univariable analysis, but 
not in the multivariable analysis. 
Regarding factors related to the LRRC, age ≥80 years at time of diagnosis (OR 4.82, 95% CI: 
2.37-9.80) was the factor that most significantly increased the risk of treatment with palliative 
intent (Table 9). Presence of symptoms (OR 2.79, 95% CI: 1.56-5.01), presence of 
hydronephrosis (OR 1.95, 95% CI: 1.06-3.58) and a non-central location of the LRRC (OR 
1.79, 95% CI: 1.15-2.79) were also associated with a higher probability of treatment with 
palliative intent. Co-morbidity had no association to treatment intention. 
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Table 7 Patient and primary tumour characteristics of all patients included in study II-IV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
All patients 
 n=426 
Sex 
  Male 
  Female  
 
231 (54.2) 
195 (45.8) 
Ageⱡ 
  <60 
  60-69 
  70-79 
  ≥80 
  Median (range) 
 
71 (16.7) 
115 (27.0) 
141 (33.1) 
99 (23.2) 
72 (27-92) 
Tumour height 
  High (11-15 cm)   
  Medium (6-10cm) 
  Low (0-5 cm)  
  Data missing 
 
109 (25.6) 
152 (35.7) 
156 (36.6) 
9 (2.1) 
Neoadjuvant treatment 
  No trt 
  (C)RT 
  Data missing 
 
263 (61.7) 
162 (38.0) 
1 (0.2) 
Type of surgery 
  LAR 
  APR 
  Hartmann’s proc 
 
217 (50.9) 
144 (33.8) 
65 (15.2) 
(y)pT-stage 
  T1-T2 
  T3-T4 
  Data missing 
 
81 (19.0) 
334 (78.4) 
11 (2.6) 
Stage 
  I 
  II 
  III 
  Data missing 
 
55 (12.9) 
128 (30.0) 
237 (55.6) 
6 (1.4) 
Post-operative complication 
  No 
  Yes 
  Data missing 
 
239 (56.1) 
181 (42.5) 
6 (1.4) 
Re-operation within 30 days 
  No 
  Yes 
  Data missing 
 
380 (89.2) 
42 (9.9) 
4 (0.9) 
Margin status of primary 
surgery 
  R0 
  R1 
 
325 (76.3) 
101 (23.7) 
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Table 8 Local recurrence characteristics of all patients included in study II-IV 
   
 
 
All patients 
n=426 
Age 
  <60 
  60-69 
  70-79 
  ≥80  
  Median age (range) 
 
59 (13.8) 
98 (23.0) 
138 (32.4) 
131 (30.8) 
74 (31-93) 
Time to LRRC 
  <12 months 
  ≥12 months 
  Median months (range) 
 
112 (26.3) 
314 (73.7) 
20 (1-95) 
Symptoms at diagnosis 
  No 
  Yes  
 
Type of symptom 
  Pain 
  Anal/perianal symptom 
  Change of bowel habits 
  Urogenital symptom 
  Reduced general cond. 
  Palpable tumour 
  Lower limb symptom 
 
61 (14.3) 
360 (84.5) 
 
 
130 (30.5) 
103 (24.2) 
77 (18.1) 
67 (15.7) 
30 (7.0) 
24 (5.6) 
16 (3.8) 
Hydronephrosis 
  No 
  Yes 
 
348 (81.7) 
78 (18.3) 
Location of LRRC 
  Central 
  Non-central 
 
213 (50.0) 
213 (50.0) 
Co-morbidity# 
  No 
  Yes 
 
Type of co-morbidity 
  Cardiovascular disease 
  Diabetes 
  Previous other cancer 
  Synchronous cancer 
  Asthma/COPD 
  Neurological disease 
  Other 
 
165 (38.7) 
261 (61.3) 
 
 
183 (43.0) 
44 (10.3) 
29 (6.8) 
37 (8.7) 
28 (6.6) 
19 (4.5) 
23 (5.4) 
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Table 9 Local recurrence related factors with significant association with treatment intention, 
n=426 
 
 
 
Variable 
 
Treatment with   
curative intent, 
n=149 
 
Treatment with 
palliative intent, 
n=277 
 
 
Multivariable  
OR (95% CI) 
 
 
Multivariable  
p-value 
Age 
  <60 
  60-69 
  70-79 
  ≥80  
 
32 (21.5) 
42 (28.2) 
41 (27.5) 
34 (22.8) 
 
27 (9.7) 
56 (20.2) 
97 (35.0) 
97 (35.0) 
 
ref 
2.09 (1.04-4.20) 
3.62 (1.84-7.13) 
4.82 (2.37-9.80) 
 
 
 
 
<0.001 
Time to LRRC 
  <12 months 
  ≥12 months 
 
44 (29.5) 
105 (70.5) 
 
68 (24.5) 
209 (75.5) 
 
 
 
 
Symptoms at diagnosis 
  No 
  Yes  
 
Type of symptom 
  Pain 
  Anal/perianal symptom 
  Change of bowel habits 
  Urogenital symptom 
  Reduced general cond. 
  Palpable tumour 
  Lower limb symptom 
 
36 (24.2) 
111 (74.5) 
 
 
32 (21.5) 
37 (24.8) 
27 (18.1) 
18 (12.1) 
7 (4.7) 
12 (8.1) 
1 (0.7) 
 
25 (9.0) 
249 (89.9) 
 
 
98 (35.4) 
66 (23.8) 
50 (18.1) 
49 (17.7) 
23 (8.3) 
12 (4.3) 
15 (5.4) 
 
ref 
2.79 (1.56-5.01) 
 
 
0.001 
Hydronephrosis 
  No 
  Yes 
 
129 (86.6) 
20 (13.4) 
 
219 (79.1) 
58 (20.9) 
 
ref 
1.95 (1.06-3.58) 
 
 
0.031 
Location of LRRC 
  Central 
  Non-central 
 
89 (59.7) 
60 (40.3) 
 
124 (44.8) 
153 (55.2) 
 
ref 
1.79 (1.15-2.79) 
 
 
0.009 
 
4.2.3 Follow-up and survival 
Median follow-up time was 8.6 (range 2.0-12.3) years and median survival from date of 
diagnosis of the LRRC was 1.1 (0-12.3) years. Overall five-year survival was 23.1% for 
patients treated with curative intent and 1.0% for patients treated with palliative intent (logrank 
p<0.001) (Figure 16). The five-year survival was 8.9% for all patients. A Cox regression 
analysis of patients treated with curative intent, revealed that the same LRRC related factors that 
influenced the selection for treatment intention also affected the risk of death, including age ≥80 
years (HR 2.44, 95% CI: 1.55-3.86), stage III primary tumour (HR 1.83, 95% CI: 1.25-2.68), 
presence of symptoms (HR 1.92, 95% CI: 1.20-3.05), non-central location (HR 1.51, 95% CI: 
1.01-2.26) and presence of hydronephrosis (HR 2.02, 95% CI: 1.18-3.44). These results were 
valid for both univariable and multivariable analysis. Figure 17 represents Kaplan-Meier 
illustrations of overall survival according to the factors of significant influence for survival in 
patients treated with curative intent. 
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Figure 16 Survival of patients treated with curative and palliative intent, n=426 
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Figure 17 Survival of patients treated with curative intent according to a) age, b) presence of 
symptoms at time of diagnosis, c) presence of hydronephrosis and d) location of the local 
recurrence, n=149 
a)                                                                            b) 
  
c)                                                                                 d) 
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4.3 PAPER III 
 
4.3.1 Characteristics 
The characteristics of all 426 patients of study III are illustrated in Table 6 and 7 and are more 
thoroughly described in the characteristics section of paper II. In this study, 221 patients were 
aged <75 years and 205 patients were aged ≥75 years. 117 patients (27.5%) had their LRRC 
diagnosed during period 1 (1995-1998), 204 (47.9%) got a diagnosis in period 2 (1999-2002), 
and 105 (24.6%) during period 3 (2003-2007).  
 
4.3.2 Treatment and resection margins 
Of the 149 patients treated with curative intent, 63 (42.3%) received neoadjuvant treatment and 
of these 41 received RT, 18 had CRT and four received ChT only (Table 10). 121 (81.2%) 
patients were operated with tumour resection, 19 patients (12.8%) had explorative laparotomy 
only and nine patients (6.0%) were never operated, due to aggravated general condition, tumour 
growth during neoadjuvant treatment, patient refusal to surgery or death. 
Of the 121 patients resected with curative intent, 64 (52.9%) had an R0-resection, 31 patients 
(25.6%) had an R1-resection and 26 (21.5%) had an R2-resection. 25 patients (20.7%) received 
adjuvant chemotherapy. Patients with a non-central location of the LRRC had a five times 
higher risk of a non-radical (R1/R2) tumour resection compared with patients with a central 
tumour location (OR 5.02, 95% CI: 2.25-11.21). 
 
4.3.3 Time periods and regions 
There was a decrease in the proportion of patients treated with curative intent in period 3 
compared with the previous periods but the difference was not significant. A higher proportion 
of patients were operated with R0-resection during period 2 compared with period 1 and 3 but 
this difference was not significant either. The proportion of patients with central recurrence 
decreased over time, from 52% in period 1 and 54% in period 2 to 39% in period 3 (p=0.033). 
Regarding regions, the rate of patients with LRRC as first event varied between 3.4 to 5.8% and 
the overall national rate was 4.7%. The rate of patients treated with curative intent varied 
between 29% and 43% but the differences were not significant.  
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Table 10 Treatment characteristics of patients treated with curative intent, n=149 
  
Number (%) 
Neoadjuvant treatment 
  (C)RT 
  CT 
  No treatment 
  Data missing 
 
59 (39.6) 
4 (2.7) 
84 (56.4) 
2 (1.3) 
Surgery 
  Tumour resection 
  Explorative laparotomy 
  No surgery 
 
121 (81.2) 
19 (12.8) 
9 (6.0) 
 
4.3.4 Follow-up and survival 
Five-year survival for patients resected with curative intent was 43% after R0-resection, 14% 
after R1-resection and 4% after R2-resection (Figure 18). The most common type of first failure 
was distant metastases, affecting 30% of the R0-resected patients and 42% of the R1-resected 
patients. Local re-recurrence was significantly more common in R1-resected patients, where 
29% were affected, compared with 20% of the R0 resected patients (p=0.044). 
The risk of any failure, including re-recurrence, distant metastases or death, for R0/R1-resected 
patients was significantly affected by margin status. R1-resected patients had a doubled risk of 
failure compared with R0-resected patients in an adjusted analysis (HR 2.04, 95% CI: 1.22-
3.40). No significant associations to age, sex, time to LRRC or location of the LRRC were 
found.  
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4.4 PAPER IV 
 
4.4.1 Characteristics of treatment groups 
Of all 426 patients, 149 (35.0%) patients were treated with tumour resection, 193 (45.3%) 
recived treatment without tumour resection and 84 (19.7%) received best supportive care 
(Figure 13).  
The patients treated with tumour resection were significantly younger (median 71.9 years) than 
patients treated with best supportive care (median 79.9 years) (p<0.001). 
Fewer of the patients treated with tumour resection were symptomatic (75.2%), compared with 
the other two groups (90.2% and 88.1%) (p<0.001). The most common symptoms among the 
patients treated with tumour resection were anal or perianal symptoms (21.5%), followed by 
change of bowel habits (20.1%) and pain (18.8%). On the contrary, pain dominated as the most 
common symptom both among patients treated without tumour resection (39.4%) and patients 
treated with best supportive care (31.0%). In total, 130 (30.5%) of all patients had symptoms of 
pain. A majority of these (58.5%) were treated without tumour resection and most of the 
patients with pain (63.1%) also had a non-central location of the LRRC. 
 
4.4.2 Surgical treatment 
The 149 patients operated with tumour resection were assessed in 50 different hospitals and the 
surgery was performed in 48 hospitals, with a range of 1 to 23 operated patients per hospital 
during the study period.  
Abdominal resection was performed in 132 patients (88.6%) (Table 11). 84 patients (56.4%) 
were operated with a resection of the neorectum and in 49 of these, additional organs were 
resected simultaneously. APR was the most common procedure, performed in 65 (43.6%) of the 
resected patients, followed by HA (10.7%) and PE (8.7%). Only 12 patients (8.1%) received 
IORT. Reconstructive surgery was performed in 18 patients (12.1%) and the most common type 
was a reconstruction of the urinary tract, valid for 11 patients. 67 patients (45.0%) had local R0 
surgery, but only 64 (43.0%) received a curative treatment. 
In the 193 patients treated without tumour resection, 79 patients (40.9%) were treated with 
surgery, where creation of a stoma was the most common procedure.  
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Table 11 Surgical details for patients treated with tumour resection for local recurrence, n=149 
 
 
Variable 
 
Number (%) 
 Surgery 
  Abdominal resection 
    Total pelvic exenteration 
    Colorectum/neorectum only 
    Colorectum/neorectum + other organ 
    Other organ only 
   
    Resected other organ* 
      -small bowel 
      -vagina/vulva 
      -internal genitals# 
      -soft tissue 
      -sacrum/coccyx 
      -colon 
      -urinary tract organs 
      -iliac lymph nodes 
      -pelvic wall 
   
  Local excision 
 
 
132 (88.6) 
13 (9.8) 
35 (26.5) 
49 (37.1) 
35 (26.5) 
 
 
36 
22 
15 
13 
8 
5 
4 
1 
1 
 
17 (11.4) 
  Resection margins 
    R0 
    R1 
    R2 
 
67 (45.0) 
32 (21.5) 
50 (33.5) 
  Curative surgery 
    No  
    Yes 
 
85 (57.0) 
64 (43.0) 
 
 
4.4.3 Complications 
Early postoperative complications (<30 days after surgery) were common and found in 83 of all 
228 operated patients (36.4%). The frequency was significantly higher among patients treated 
with tumour resection than among those operated without tumour resection (41.6% vs 26.6%, 
p=0.022). Still, the non-resected patients had a significantly higher postoperative mortality 
(10.0% vs 2.4%, p=0.002). The most common surgical complications among patients treated 
with tumour resection were intraabdominal abscess, wound infection, anastomotic leakage, 
bleeding and fistula. Among the non-resected patients, ileus, anastomotic leakage and bleeding 
were most common. 
Late complications (≥30 days after surgery), occurred in 35 (54.7%) of the curatively operated 
patients and pain was the most common problem.  
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4.4.4 Follow-up and survival 
Three-year survival was 60.6% for patients treated with a curative tumour resection, 18.6% after 
non-curative resection and 8.3% after treatment without tumour resection (Figure 19a).  
Among patients receiving surgical treatment, presence of postoperative complications was 
associated with a worse survival. However, a curative treatment was more important than 
absence of complications, since curatively operated patients with postoperative complications 
had a better survival than non-curatively resected patients without complications (Figure 19b). 
 
 
Figure 19 Kaplan-Meier plots illustrating overall survival in a) all patients, according to type 
of treatment (n=426), b) all patients receiving curative and non-curative surgical treatment, 
according to complication status (n=224) 
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5 DISCUSSION 
 
Many changes in management and treatment of patients with primary RC have been 
implemented during the last decades, including improved preoperative staging with MRI, the 
TME-technique, preoperative RT in selected patients, MDT conferences and follow-up 
programs. These changes have resulted in a marked decrease of the LRRC rate and a major 
improvement of the survival rates for patients with RC. According to the SCRCR, the relative 
five-year survival for patients with RC is today 80% for stage I-III1. However, 5-15% of the 
patients suffer a LRRC and 20-25% get distant metastases after radical primary surgery and for 
these patients, symptoms are severe, prognosis is poor and treatment options are few. The 
choice may stand between a potentially curative outcome at the cost of half the pelvis and one 
limb or a palliative treatment with severe pain, complicating perineal fistulas and a short life 
expectancy. This is a tough decision for both the patient and treating surgeon and therefore it is 
essential that there are good, evidence-based grounds for the treatment decision. 
 
5.1 TIME TO LRRC 
Time to LRRC was not a prognostic factor for LRRC survival in the registry-based study (study 
I). The lack of influence of this variable was confirmed in the following studies based on data 
from medical records, as no impact was seen on the selection for curative treatment (paper II) or 
the risk of any failure in R0/R1 resected patients (paper III). In paper IV, it was significantly 
more common for patients with LLR to be treated without tumour resection than to have a 
tumour resection (60% vs 40%, p=0.034). This analysis was however univariable, the 
significance was small and the result must be interpreted with caution. It has been hypothesised 
that patients with ELR have a worse prognosis than patients with LLR, possibly as they are less 
likely to have had RT or due to a more aggressive tumour type in patients with ELR244-247. An 
early diagnosed LRRC could also imply a more extensive residual microscopic tumour spread 
than in late recurrences. Other reports have however not shown any impact on prognosis of this 
variable248-251. In summary, the results of the papers of this thesis establish that time to LRRC 
did not influence neither the selection for treatment nor the outcome of treatment.   
 
5.2 PREDICITIVE FACTORS FOR TREATMENT INTENTION 
An optimal selection process for treatment with curative intent necessitates a complete 
assessment, adequate staging and discussion at an MDT conference. 80% of the patients in 
study II-IV were assessed with CT or MRI, which means that every fifth patient did not have an 
acceptable local preoperative assessment. It may be expected that some patients have an 
affected general condition and are not suitable for either curative or palliative treatment and a 
complete assessment may therefore have been bypassed in these cases. The annual report from 
the SCRCR 2016 reported that more than 95% of all patients with primary RC were discussed 
at a preoperative MDT conference during 20161. Unfortunately, information about how many 
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patients that had been discussed at MDT meetings for their LRRC could not be extracted from 
the medical records in a reliable way, but it is not likely to be as high as 95%. Regarding this, it 
seems that there is room for improvement of the preoperative routines for patients with LRRC.  
In study II, it was found that advanced age, advanced primary tumour, previous APR or HA 
surgery, presence of symptoms (pain in particular) and a non-central tumour location were 
predictive factors for treatment with palliative intent. These findings are not very controversial, 
as these factors have previously been shown to be associated to a worse prognosis152,247,252. It 
was however surprising that there was no correlation to co-morbidity, as a high co-morbidity 
may be an obstacle to surgery. One explanation to this might be that there are several methods 
to report co-morbidity. The Charlson comorbidity index was developed to allow for a useful 
classification of co-morbidity in risk-analyses in longitudinal studies253. Both presence and 
severity of a condition is valued and assigned a weighted index (1, 2, 3 or 6), which is 
summarised in each patient. The ASA (American Society of Anaesthesiologists) physical status 
classification system is more complex and provides a staging (I-VI) of a patient’s current status 
in relation to the planned surgical procedure254. None of these methods were used in the studies 
of this thesis, as it was difficult to interpret this information from the medical records. 
Only 14% of the patients with LRRC were asymptomatic and detected at planned screening 
visits (paper II-IV). It would be relevant to assess if a screening programme, aimed at early 
detection of LRRC in high risk patients, could result in a potentially curative treatment in a 
higher proportion of patients. The US Multi-Society Task Force on Colorectal Cancer suggests 
local surveillance with flexible sigmoidoscopy or endoscopic ultrasound every 3-6 months 
during the first 2-3 years in patients with an increased risk of local recurrence after treatment for 
primary rectal cancer. However, the evidence for an improved survival with this management is 
low and randomised controlled trials are lacking255. In addition, the rate of anastomotic LRRC 
detectable with endoscopy is probably low after appropriate TME surgery. A regular follow-up 
with pelvic MRI in high risk patients may be more appropriate with an enhanced chance of 
early detection of pelvic recurrences256. 
 
5.3 TIME TRENDS 
Several studies have illuminated the advantages of a multidisciplinary management in complex 
diseases, both in terms of selection for treatment and treatment results57,58,257. Kontovounisos et 
al showed a decrease in the proportion of patients operated on for LRRC from 36% to 28% 
between 2010 and 201460. The same trend was seen in our material (38% to 29%), but the 
difference was not significant. It is possible that this indicates a trend towards a more thorough 
selection of patients for surgery in recent years, possibly through an increased MDT 
management. If this is the case, it would also imply rising R0 resection rates. This could not be 
seen in our material, possibly due to a power problem or too narrow time intervals, but it may 
also be that the full effect of the more thorough selection for treatment has not yet been seen.  
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A time trend that however was seen in study III was an increased rate of non-central recurrences 
over time. This trend has been observed in previous studies and may also influence the selection 
for treatment as posterior and lateral recurrences are more difficult to operate158-160.  
 
5.4 TREATMENT OF LRRC 
One third of the patients with LRRC were treated with abdominal tumour resection (study IV) 
and of these, only 10% were treated with PE despite a non-central tumour involvement in 40% 
of the resected patients. LRRC tumours with a non-central location have the worst prognosis 
and are the most challenging to operate, requiring extended excisions176. The results of the 
present studies however indicate that some patients may not have received adequate surgical 
treatment. The reasons for this are unknown, but insufficient preoperative staging, lack of 
multidisciplinary competence and an overall pessimistic view of the condition LRRC are 
possible explanations. There are few previous population-based studies to compare our results 
with and none with a nation-wide perspective124,125. Smaller population-based studies, covering 
limited regions, have shown similar resection rates, but a review article from 2009 including 19 
papers on LRRC, revealed higher resection rates, between 40-50%202. The represented studies 
were almost exclusively performed in highly specialised centres, which entails a risk of 
selection bias. 
In total, 29% of the patients resected with curative intent had not received RT, neither during 
the primary nor recurrent disease (study III). This is a surprisingly large proportion and reasons 
for this may be the lack of uniform treatment guidelines and MDT approach. Although few 
studies have evaluated the effects of RT or CRT specifically on LRRC, there is forceful 
evidence of the beneficial prognostic effect of RT on pelvic cancer61,258,259. According to the 
Beyond TME collaborative group, preoperative CRT is today recommended to all patients with 
LRRC, unless there are contraindications150. 
Centralisation of the management of complex diseases to highly specialised centres in order to 
improve the prognosis has grown parallel to the increased MDT strategy. A study of patients 
with oesophageal cancer showed that a centralisation of surgery led to an unchanged number of 
complications but a significant increase in survival260. It is however difficult to point out a 
specific factor playing the crucial role in these results. In the case of LRRC there is reason to 
believe that the access to multiple disciplines and other resources play a crucial role and the 
unit’s overall accumulated experience may be more important than that of the individual 
surgeon. 
 
5.5 METHODOLOGY  
The main strengths of the four papers are that they are population-based, covering a nation-wide 
cohort with a long follow-up time. To our knowledge, paper IV is the first nation-wide study 
reporting detailed data on the surgical treatment of LRRC. Studies II-IV also have the 
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advantage of being based on validated data from medical records, moreover including a survey 
of multiple new variables, not previously reported to any registry.  
Of course, there are also some limitations. Firstly, since the selection of patients with LRRC for 
all four studies is based on the diagnoses reported to the SCRCR, the risk of underreporting 
must be taken into account. Jörgren et al. showed that there was a discrepancy of 11% between 
the registry and medical journals regarding the reporting of LRRC diagnosis. This analysis was 
based on the LRRC diagnoses actually reported to the registry and provides no information 
about how many patients with LRRC that were not reported. It is difficult to assess the 
proportion of patients that may have been missed, but it is a reasonable guess that these patients 
are few and mainly consist of those with very late recurrences or a very poor general condition. 
Secondly, a review of a large number of medical records entails the risk of misclassifications 
due to misinterpretations. Since the whole review was made by the same person, these errors 
could be either sporadic or systematic. In order to avoid systematic errors, regular 
reconciliations were held with the research team, but minor sporadic errors may have occurred. 
These should however be few and of minor statistical importance. Thirdly, all four studies are 
performed on the same cohort of patients which introduces the risk of multiple significance 
problems. This is a well-known statistical problem, which implies an increased risk of false 
positive results (type I errors) when performing a large series of analyses on the same group of 
patients261. Hence, it is possible that some of the values of the studies do not reflect a true 
statistical significance but, in fact, are results by chance. Regarding this, caution should be taken 
while interpreting individual values. Finally, despite the population-based large cohort, the lack 
of significance in some of the analyses may be due to a power problem, leading to type II errors. 
This is especially valid for the subgroup analyses with smaller analysed groups.  
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6 CONCLUSIONS 
 
Overall conclusion 
A minority of patients with LRRC were treated with curative intent and resection surgery was 
performed at a high number of surgical centres. A curative resection of the LRRC is essential 
for a favourable prognosis. There is room for an enhanced multidisciplinary management of 
these patients, which could result in better selection for curative surgery. 
 
Specific conclusions 
Time to LRRC had no impact on survival calculated from diagnosis of LRRC. All patients 
should be assessed for potential curative surgery, disregarding time to LRRC. 
A minority of the patients with LRRC were treated with curative intent. Positive predictive 
factors for treatment with curative intent were young age, AR at primary surgery, a low stage of 
the primary tumour, absence of symptoms, absence of hydronephrosis and a central location of 
the LRRC. The same factors were associated with a favourable prognosis among patients 
treated with curative intent. 
There were no significant time trends or regional differences regarding the selection for 
treatment with curative intent or the proportion of completely resected tumours. There was 
however a significant increase in the proportion of patients with a non-central LRRC over time 
and these patients also had a higher likelihood of non-radical tumour resection. The prognosis 
was poor for all patients with LRRC, but nearly half of the patients treated with radical tumour 
resection survived five years.  
Surgical resection of the LRRC was performed in a minority of the patients and APR was the 
most common resection procedure. Less than half of the patients were treated with multi-organ 
resection. Complications were common and were associated with an inferior survival rate. 
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7 FUTURE PERSPECTIVES 
 
Many issues concerning LRRC are still to be investigated. Since TME-surgery, modern RT 
treatment and routines for multidisciplinary management were successively implemented 
during the study period of the papers of this thesis, the full effect of this management has not yet 
been shown. Therefore, it would be interesting to investigate what factors that predict treatment 
with curative intent in a more recent cohort, where modern rectal cancer treatment has been 
practiced in full. It would also be interesting to find out what types of procedures that are 
performed today and whether the trend of an increasing rate of non-central recurrences persists. 
It has previously been indicated that women receive RT to a lower extent than men in primary 
RC262. Another study of patients with RC has shown a lower risk of death in married patients 
and patients with high incomes263. No differences between sexes in the selection for treatment 
were found in the studies included in this thesis, but it is possible that factors like educational 
level, income level or civil state have an influence on the selection for treatment of LRRC. This 
will be investigated for the cohort included in paper II-IV, with additional data from Statistics 
Sweden. 
There are also other factors that may influence the outcome of surgery. It would be interesting 
to go even further in the investigation of what factors may predict radical surgery of a LRRC. A 
study of whether MRI-findings may predict complete or incomplete tumour resection has been 
initiated in a recent Stockholm material. This study may give additional information about what 
patients may receive the greatest benefit from LRRC surgery. A study of the current surgical 
treatment of patients with LRRC at a tertial referral centre (Karolinska University Hospital) has 
been completed by our research group and will be published shortly.  
A decreasing proportion of patients treated with curative intent entails an increasing number of 
patients not having curative surgery. What happens to them? What is their quality of life? A 
more thorough investigation of the given palliative treatment in patients with LRRC and their 
QoL would give important information about this specific group of patients.  
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8 SAMMANFATTNING PÅ SVENSKA 
 
Cancer i tjock- och ändtarm (kolorektalcancer) är den tredje vanligaste cancerformen i världen 
och drabbar årligen 1,4 miljoner människor. Av dessa utgörs en tredjedel av cancer i ändtarmen 
(rektalcancer), vilket drabbar cirka 2000 svenskar varje år. Sjukdomen drabbar i huvudsak äldre 
och medianåldern vid diagnos är 72 år. Ändtarmscancer behandlas genom kirurgiskt 
borttagande av ändtarmen och därefter sammankoppling av de kvarvarande tarmändarna 
alternativt stomi. Prognosen för patienterna har förbättrats markant under de senaste 
decennierna, beroende på flera faktorer: En förbättrad kirurgisk metod (s.k.TME), där fettskiktet 
intill ändtarmen tas bort tillsammans med tumören, introducerades i början av 90-talet, vilket 
ledde till förbättrade resultat. Tillägg av strålbehandling med eller utan kombinerad 
cellgiftsbehandling före operation av tumören minskar ytterligare risken för tumöråterfall. 
Införandet av ett multidisciplinärt omhändertagande (MDT), där fynd och behandling rörande 
varje patient diskuteras mellan onkolog, kirurg, patolog och radiolog vid särskilda 
behandlingskonferenser har ytterligare bidragit. En standardiserad utredningsgång med 
magnetkameraundersökning (MRI) för bedömning av lokal tumörutbredning och 
datortomografi (CT) för att påvisa eller utesluta fjärrspridning har lett till en förbättrad 
gradering av tumörutbredning. Standardiserade uppföljningsprogram efter behandling har också 
införts, i syfte att hitta eventuella återfall på ett tidigt, behandlingsbart stadium.  
Ett lokalt tumöråterfall, så kallat lokalrecidiv (LRRC), innebär en återväxt av tumör i lilla 
bäckenet efter tidigare botande kirurgisk behandling. LRRC drabbar idag ca 5-9% av de som 
tidigare opererats för primär ändtarmscancer, jämfört med 30-40% för 30 år sedan. Vanliga 
symptom vid såväl primär RC som LRRC är blod i avföringen och ändrade avföringsvanor. Vid 
LRRC kan man dessutom få blödningar från slidan, smärta runt ändtarmen och urinträngningar. 
Utredning görs vanligen med magnetkameraundersökning (MRI) för lokal tumörgradering, 
skiktröntgen (CT) för att utesluta fjärrmetastaser och vävnadsprov (biopsi) från tumören för att 
bekräfta diagnosen. Fynden diskuteras därefter vid MDT-konferens. Beroende på lokalisationen 
av patients LRRC krävs olika typer av behandling, men nationella riktlinjer för behandling av 
LRRC saknas i Sverige. Ett kirurgiskt ingrepp med borttagande av hela tumören är den enda 
chansen till bot. En behandling med botande syfte (kurativ intention) kan innebära borttagande 
av kvarvarande ändtarm, men ibland även borttagande av livmoder, äggstockar, prostata, 
urinblåsa, del av korsbenet (sakrektomi), och halva bäckenbenet (hemipelvektomi). I vissa fall 
är operation inte möjlig på grund av alltför omfattande lokal tumörväxt, inoperabel 
fjärrspridning eller andra komplicerande sjukdomar. I dessa fall kan det bli fråga om bromsande 
(palliativ) behandling eller enbart symptomlindrande åtgärder (best supportive care, BSC). 
Skillnaden är stor vad gäller överlevnad för de patienter som genomgår en botande operation 
och de som inte gör det. Av de som genomgår botande kirurgi kan upp till 60% överleva i fem 
år, medan motsvarande siffra för alla LRRC-patienter sammantaget är under 10%. Sjukdomen 
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innebär dessutom ofta svårt lidande för de drabbade med blödningar, smärta och återkommande 
infektioner.  
Syftet med denna avhandling var att studera hur patienter med LRRC i Sverige utreds, 
behandlas och vilken prognos de har.  
I arbete I undersöktes huruvida tiden mellan operation för primär ändtarmscancer till diagnos 
av LRRC hade någon betydelse för överlevnaden räknat från upptäckten av LRRC. Data 
rörande patienten, primärtumören, tidpunkt för LRRC diagnos och uppföljning inhämtades från 
Svenska Kolorektalcancerregistret (SCRCR), som är ett nationellt register dit alla diagnoser av 
ändtarmscancer och LRRC rapporteras. Samtliga patienter som opererats för primär 
ändtarmscancer mellan 1995-2002 och fått ett LRRC inom 5 år inkluderades och analyserades. 
Totalt inkluderades 386 patienter. Resultaten visade att tiden till LRRC inte hade någon 
betydelse för överlevnaden. Däremot var överlevnaden bättre vid låg ålder, mindre avancerat 
stadium på primärtumören och kirurgiskt borttagande av patients LRRC. 
Arbete II syftade till att undersöka vilka faktorer som ligger till grund för valet av kurativt 
syftande behandling kontra icke-kurativt syftande behandling (palliativ eller BSC) hos patienter 
med LRRC. Liksom i arbete I inkluderades de patienter som opererats för primär 
ändtarmscancer mellan 1995-2002, men denna gång inhämtades uppgifterna från journalkopior 
från behandlande sjukhus och antalet inkluderade patienter skiljde sig därför från arbete I. 
Journalerna granskades både med avseende på egenskaper hos och behandling av 
primärtumören och med inhämtande av uppgifter om LRRC. Felregistrerade patienter uteslöts. 
Totalt 426 patienter inkluderades, varav en dryg tredjedel (35%) erhöll behandling med kurativ 
intention. Faktorer som ökade sannolikheten för detta var låg ålder, symptomfrihet vid diagnos 
och ett LRRC enbart beläget i tarm, urinvägar eller inre könsorgan. Vid undersökning av enbart 
de patienter som behandlats med kurativ intention, så innebar förekomst av dessa faktorer en 
förbättrad överlevnad. Av de som behandlats med kurativ intention överlevde 23% i fem år eller 
mer, medan motsvarande siffra var 9% för alla patienter med LRRC. 
I arbete III undersöktes om det fanns några skillnader mellan tidsperioder eller behandlande 
regioner avseende behandlingsintention eller resultatet av kirurgin. Samma 426 patienter som 
ingick i arbete II analyserades. Resultaten under tre tidsperioder (1995-1998, 1999-2002, 2003-
2007) och i 6 behandlande regioner jämfördes. Varken region eller tidsperiod påverkade valet 
av behandlingsintention eller resultat av kirurgin (radikalitet). Däremot hade andelen patienter 
med LRRC utanför tarm, urin- och könsorgan ökat över tid och dessa löpte högre risk för en 
icke-botande (icke-radikal) operation. För dem där ett fullständigt (radikalt) borttagande av 
tumören kunde uppnås var överlevnaden god, 43% överlevde i minst fem år, jämfört med de 
patienter där operationen var icke-radikal, där överlevnaden var 14%. 
I arbete IV undersöktes den givna behandlingen närmare hos samma patienter som inkluderats 
i arbete II och III. En tredjedel (35%) behandlades med kirurgiskt borttagande av LRRC. Hos 
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dessa var borttagande av del av tarmen det vanligaste ingreppet. En tiondel av patienterna 
genomgick borttagande av samtliga organ i lilla bäckenet (del av tjock/ändtarm, urinblåsa, inre 
könsorgan), så kallad total bäckenutrymning. En femtedel av patienterna opererades i 
symptomlindrande syfte utan borttagande av tumör, så kallad palliativ operation. Detta utfördes 
oftast i form av uppläggning av stomi på grund av tumörorsakat tarmhinder. 
Operationsorsakade komplikationer var vanliga och medförde en sämre prognos både hos de 
som opererats med kurativ respektive icke-kurativ intention. Den viktigaste faktorn för en god 
prognos var dock ett radikalt borttagande av LRRC.   
Sammanfattningsvis så visar denna avhandling att en minoritet av patienterna med LRRC i 
Sverige behandlades med kurativt syftande behandling och att ett radikalt borttagande av LRRC 
är nödvändigt för en god prognos. Tid till recidiv hade ingen betydelse för prognosen hos 
patienter med LRRC, varför denna faktor inte bör räknas med vid ställningstagande till 
behandling. Flera faktorer hade betydelse för urvalet av patienter för kurativt syftande 
behandling och samma faktorer hade även betydelse för överlevnaden, varför urvalet tycks vara 
adekvat. Kirurgisk behandling av LRRC är komplex och kan kräva kunskap och engagemang 
från flera kirurgiska specialiteter. Det multidisciplinära omhändertagandet kan sannolikt 
utvecklas ytterligare, vilket kan leda till färre komplikationer och bättre överlevnad. 
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